

الجمهورية الجزائرية الديمقراطية الشعبية وزارة التعليم العالي والبحث العلمي

**PEOPLE'S DEMOCRATIC REPUBLIC OF ALGERIA
MINISTRY OF HIGHER EDUCATION AND SCIENTIFIC RESEARCH**



University years 2023/2024

Higher School of Biological Sciences of Oran

Department of Second cycle

**Pedagogical Handout
Subject**

**Molecular Genetic of
eukaryote**

Option: Molecular Biology

Specialty: Biotechnology

Sector: Biological Sciences

Domain: Science of Nature and Life

Realized by :

Dr. Wefa BOUGHRARA

Subject taught during the university years

2022/2023
2023/2024

Reading Committee

Pr ABERKANE Meriem Samia
Pr TABET AOUL Nacera

Preamble

Welcome to the world of molecular eukaryotic genetics, where the complex mechanisms governing life at the molecular level are unraveled through the lens of diverse model organisms. This book embarks on a journey through the intricate landscapes of genetic regulation, inheritance, and molecular interactions that define eukaryotic organisms. *Molecular Eukaryotic Genetics: From Models to Mechanisms* provides a comprehensive exploration of the molecular underpinnings that define eukaryotic organisms. From foundational principles elucidated through diverse model organisms to advanced insights into gene regulation, genome stability, developmental genetics, and disease mechanisms, this book bridges fundamental research with translational applications in medicine, agriculture, and biotechnology. It serves as an indispensable resource for students, researchers, and professionals seeking to unravel the molecular complexities of eukaryotic genetics in the quest for knowledge and innovation.

Chapter 1: Model Organisms in Molecular Genetics: The first chapter introduces key eukaryotic models that have revolutionized our understanding of molecular genetics. From the microscopic elegance of *Caenorhabditis elegans* to the simplicity and utility of *Saccharomyces cerevisiae* (yeast), and from the genetic mosaics of *Drosophila melanogaster* (fruit fly) to the physiological parallels of *Mus Musculus* (mouse), each organism offers unique insights into fundamental genetic processes. Plants, with their genetic diversity and agricultural significance, complete this comprehensive exploration. Through these models, readers gain profound insights into gene regulation, developmental biology, and evolutionary genetics, setting the stage for deeper molecular explorations.

Chapter 2: Molecular Basis of Human Genetic Diseases: Delving into the heart of molecular genetics, this chapter elucidates the intricate mechanisms that control gene expression in eukaryotic organisms. Topics include transcriptional regulation, post-transcriptional modifications, epigenetic mechanisms, and the role of non-coding RNAs in shaping gene activity. Case studies highlight how these mechanisms influence development, differentiation, and responses to environmental cues, offering a comprehensive view of gene regulation dynamics.

Chapter 3: Cancer Genetics: Genome stability is essential for the fidelity of genetic information across generations. This chapter explores the molecular mechanisms that safeguard genome integrity, including DNA replication fidelity, repair mechanisms for DNA damage, and the role of telomeres and centromeres in chromosome stability. Discussions on genome

maintenance in the context of aging, environmental stress, and disease underscore the importance of these mechanisms in cellular homeostasis and organismal health.

Developmental processes are orchestrated by intricate molecular networks that regulate cell fate determination, tissue patterning, and organogenesis. This chapter explores how molecular genetics unravels the mechanisms underlying these processes, from signaling pathways and morphogen gradients to the role of master regulatory genes and epigenetic modifiers. Insights into developmental disorders and evolutionary adaptations provide a holistic understanding of developmental genetics.

The final chapter explores how molecular genetics illuminates the genetic basis of complex traits and diseases in eukaryotic organisms. Topics include quantitative genetics, genome-wide association studies (GWAS), and the identification of causative variants in human diseases. Case studies illustrate how molecular genetics has transformed our understanding of genetic predisposition, disease mechanisms, and potential therapeutic interventions.

,

Summarize

Abbreviation List.....	7
Figures List	9
Chapter I: Eukaryotic Genetics Models.....	12
I. Introduction	13
II. Nematode <i>Caenorhabditis elegans</i>	13
II.1. Description	13
II.2. Genetics advantages	15
II.3. Genetics description	16
II.4. Cytogenetic and <i>C. elegans</i>	17
II.5. Longevity Genetic markers and <i>C. elegans</i>	18
II.6. The epigenetic and <i>C. elegans</i>	22
II.7. The <i>RNAi</i> and <i>C. elegans</i>	25
II.8. The <i>miRNA</i> and <i>C. elegans</i>	27
II.9. Limits of <i>C. elegans</i> model	28
III. Yeasts	29
III.1. Description.....	29
III.2. Genetics advantages.....	31
III.3. Genetics description.....	32
III.4. The cystathionine beta-synthase (CBS) and yeast model.....	33
III.5. Functional Analysis of Separated Alleles in Yeast (FASAY).....	35
III.6. The Functional Impact of P53 Hotspot Mutations, p63, and p73 in Yeast Using FASAY	36
III.7. The pathogenic effects of mutated α -synuclein and huntingtin proteins in yeast models.....	38
III.8. The Epstein-Barr Virus (EBV)-Related Tumors in Yeast Models.....	39
III.9. Limits of yeast model	39
IV. <i>Drosophila melanogaster</i>	40
IV.1. Description.....	40
IV.2. Genetics advantages.....	41
IV.3. Genetics description.....	42
IV.4. Polytene chromosome	43
IV.5. The puffs	43
IV.6. The P element.....	44

IV.7. The Balancer chromosome.....	45
IV.8. The GAL4/UAS system.....	46
IV.10. The FLP/FRT system.....	47
IV.11. Limit of <i>Drosophila melanogaster</i> model.....	49
V. Mouse <i>Mus Musculus</i>	49
V.1. Description	49
V.2. Genetics advantages	50
V.3. Genetics description	51
V.4. Transgenic and Knockout Mouse Models in Disease Research	51
V.5. CRISPR-Cas9	53
V.6. A knock-in mouse model.....	54
V.7. Limit of <i>Mouse Mus Musculus</i>	55
VI. Plants.....	56
VI.1. Description.....	56
VI.2. Genetics advantages.....	58
VI.3. Genetics description.....	58
VI.4. Rice (<i>Oryza sativa</i>): A Model for Monocots	59
VI.5. <i>Physcomitrella patens</i> : A Model for Bryophytes	60
VI.6. Molecular genetics tools used in the study of model plants.....	60
VI.7. Limits of plants model	61
Chapter II: Molecular Basis of Human Genetic Diseases.....	62
I. Positional cloning	63
II. Chromosomal abnormality.....	64
II.1. Background.....	64
II.2. Identification and definition of landmarks, regions, and bands	64
II.3. Numerical Anomalies	65
II.4. Structural Anomalies	66
III. Position-Independent Disease Gene Identification Strategies	68
III.1. Diagnosis Using Genetic Markers	69
IV. Testing a Candidate Gene Defined by Positional Cloning	71
IV.1. Gene Identification and Sequencing.....	71
IV.2. Mutation Analysis	71
IV.3. Functional Studies.....	72
IV.4. Genetic Linkage and Association Studies	72
IV.5. Animal Models	72
IV.6. Rescue Experiments.....	72

IV.7. Pathway Analysis:	73
V. Identifying Causative Variants from Association Studies	73
VI. Eight Examples of Disease Gene Identification	74
VI.1. The Duchenne muscular dystrophy (DMD)	74
VI.1.1. Description	74
VI.1.2. Genetic Description	75
VI.1.3. Technique Used for Diagnosis	76
VI.2. Cystic fibrosis	77
VI.2.1. Description	77
VI.2.2. Genetic Description	78
VI.2.3. Technique Used for Diagnosis	79
VI.3. Branchio-Oto-Renal Syndrome	79
VI.3.1. Description	79
VI.3.2 Genetic Description	80
VI.3.3. Technique Used for Diagnosis	81
VI.4. Multiple sulfatase deficiency	81
VI.4.1. Description	81
VI.4.2. Genetic Description	82
VI.4.3. Technique Used for Diagnosis	83
VI.5. Intestinal lactase persistence	83
VI.5.1. Description	83
VI.5.2. Genetic Description	84
VI.5.3. Technique Used for Diagnosis	85
VI.6. CHARGE syndrome	85
VI.6.1. Description	85
VI.6.2. Genetic Description	86
VI.6.3. Technique Used for Diagnosis	86
VI.7. Breast cancer	87
VI.7.1. Description	87
VI.7.2. Genetic Description	88
VI.7.3. Technique Used for Diagnosis	89
VI.8. Crohn's disease	90
VI.8.1. Description	90
VI.8.2. Genetic Description	91
VI.8.3. Technique Used for Diagnosis	91
VII. Advances in Disease Gene Identification	92

VII.1. Alzheimer disease	92
VII.2. Age-Related Macular Degeneration (AMD)	94
VII.3. Eczema (atopic dermatitis)	96
Chapter II: Cancer Genetics	99
I. Cancer Development	100
II. Oncogenes	104
III. Tumor Suppressor Genes	108
IV. Dysregulation of Cell Cycle Control in Cancer	109
VI. Cancer and Whole Genome Studies	112
VII. Understanding the Multistep Development of Tumors	113
VIII. Data Integration: Cancer in Terms of Cell Biology	115
References	117

Abbreviation List

A: acide aminé
ADN : acide desoxyribonucléique
ADP : adenosine diphosphate
C. elegans: Caenorhabditis elegans
Age-1: aging alteration protein 1
EMS: Ethyl Methane Sulfonate
Daf-2 : dauer abnormal formation protein 2
IR/IGF-1R: insulin receptor and insulin-like growth factor-1 receptor
H: histone
Me: Methyle
UTX-1: ubiquitously transcribed TPR
HATs: histone acetyltransferases
HMTs: histone methyltransferases
RNAi: RNA interference
mRNA: messenger RNA
siRNA: small interfering RNA
miRNA: microRNA
UTR: untranslated region
CBS: cystathionine beta-synthase
FASAY: Functional Analysis of Separated Alleles in Yeast
PrPC: prion protein
HTT: Huntington
KMO: kynurenine 2,3-monooxygenase
EBV: Epstein-Barr Virus
UAS: Upstream Activation Sequence
FLP: Flippase
CRISPR/Cas9
NHEJ: non-homologous end joining
ARN: acide ribonucléique
ARNi: ARN interference
ARNm: ARN messenger
RGAP: The Rice Genome Annotation Project
RAP-DB: Rice Annotation Project Database
RNA-seq: RNA sequencing
SNPs: single nucleotide polymorphisms
SSRs: simple sequence repeats
N: Number
NGS: next-generation sequencing
GWAS: genome-wide association studies
DHPLC: quantitative PCR denaturing high-performance liquid chromatography
qPCR: quantitative PCR
eQTL: expression quantitative trait loci
DMD: Duchenne muscular dystrophy
MLPA: Multiplex Ligation-dependent Probe Amplification
CFTR: Cystic Fibrosis Transmembrane Conductance Regulator
ASO: Allele-Specific Oligonucleotide
BOR: Branchio-Oto-Renal Syndrome
EYA1: eyes absent homolog 1
aCGH: Array Comparative Genomic Hybridization

MSD: Multiple sulfatase deficiency
SUMF1: sulfatase modifying factor 1
FGE: formylglycine-generating enzyme
RFLP: restriction fragment length polymorphism
CHD7: chromodomain helicase DNA-binding protein 7
NOD2: nucleotide-binding oligomerization domain 2
ATG16L1: autophagy-related 16-like 1
IRGM: immunity-related GTPase M
AD: Alzheimer's disease
APOE: Apolipoprotein E
LOAD: late-onset Alzheimer's disease
APP: Amyloid Precursor Protein
A β : amyloid beta
CLU : Clusterin
CR1: Complement Receptor 1
TREM2: Triggering Receptor Expressed on Myeloid cells 2
PRS: Polygenic Risk Scores
AMD: Age-Related Macular Degeneration
CFH: Complement Factor H
ARMS2: Age-Related Maculopathy Susceptibility 2
HTRA1: High-Temperature Requirement A Serine Peptidase 1
FLG: Filaggrin
CML: chronic myeloid leukemia
HER2: Human Epidermal Growth Factor Receptor 2
KRAS: Kirsten Rat Sarcoma viral oncogene homolog
MYC: v-Myc Avian Myelocytomatosis Viral Oncogene Homolog
FLT3: FMS-like tyrosine kinase 3
ITDs: internal tandem duplications
AML: acute myeloid leukemia
WGS: whole genome sequencing
RB: Retinoblastoma

Figures List

- Figure 01: *Caenorhabditis elegans* life cycle.
- Figure 02: Holocentric chromosomes of *Caenorhabditis elegans*, DNA in red, kinetochores in green.
- Figure 03: Representation of neocentromere and holocentromere on different cycle of mitosis.
- Figure 04: Representation of the age experience.
- Figure 05: The dauer abnormal formation protein 2 marker on life cycle of *C. Elegans*.
- Figure 06: The impact of AGE-1 and DAF-2 on DNA.
- Figure 07: The interaction between genetics, diet, and signaling pathways in regulating aging and lifespan in *C. elegans*.
- Figure 08: The acetylation, methylation and phosphorylation of histone.
- Figure 09: Code of histone on N- terminal extremity.
- Figure 10: Histone code.
- Figure 11: Regulation of RNAi.
- Figure 12: The interaction between genetics, diet, signaling and stress pathways in regulating aging and lifespan in *C. elegans*.
- Figure 13: Representation of mi RNA.
- Figure 14: Phylogenetic tree of *C. elegans*.
- Figure 15: Test cell structure.
- Figure 16: The cystathionine beta-synthase (CBS) cycle.
- Figure 17: Model of human model with and without yeast homologue using FASAY.
- Figure 18: Representation of p53, p63 and p73 genetic organization.
- Figure 19: Normal prion protein (PrPC) and pathogenic form (PrPSc).
- Figure 20: Roles of chaperones Hsps.
- Figure 21: Picture of Thomas Hunt Morgan.
- Figure 22: *Drosophila melanogaster*'s life cycle.
- Figure 23: Polytene chromosome.
- Figure 24: The puffs specific regions observed on polytene chromosomes.
- Figure 25: Genetic organization of P element.
- Figure 26: The GAL4/UAS system.
- Figure 27: The FLP/FRT system.
- Figure 28: The transgenic and Knockout Mouse Models.
- Figure 30: A CRISPR-Cas9 technique.
- Figure 31: knock-in mouse model.
- Figure 32: Plants life cycle.
- Figure 33: Positional cloning.
- Figure 34: Identification of landmarks, regions, and bands of chromosome.
- Figure 35: Nondisjunction Diagrams.
- Figure 36: Representation of polyploidies.
- Figure 37: Reciprocal translocation.
- Figure 38: Robertsonian Translocation.
- Figure 39: Chromosome ring.
- Figure 40: muscular dystrophy.
- Figure 41: DMD gene organization.
- Figure 42: Genetic distribution of DMD.
- Figure 43: Cystic fibrosis RNF5 expression.
- Figure 44: Mutations at CFTR gene.
- Figure 45: Branchio-Oto-Renal (BOR) syndrome.
- Figure 46: EYA1 Mutations.

Figure 47: Multiple sulfatase deficiency.
Figure 48: SUMF1 Mutations.
Figure 49: Lactase Catalysis.
Figure 50: MCM gene organization.
Figure 51: CHD7 mutations.
Figure 52: Hereditary of breast cancer.
Figure 53: BRACA1, BRCA2 mutations.
Figure 54: NOD2 associates Crohn's disease.
Figure 55: NOD2 gene organization.
Figure 56: Abnormal cleavage of amyloid precursor protein.
Figure 57: PSEN 1,2 mutations.
Figure 58: Complement Factors pathway.
Figure 59: ARMS2 gene organization.
Figure 60: HTRA1 pathway.
Figure 61: Development of malignant tumor.
Figure 62: Cancer etiology.
Figure 63: Normal and cancer cell division.
Figure 64: Sporadic and heredity form of cancer.
Figure 65: Viral infections involved on cancer.
Figure 66: Philadelphia chromosome.
Figure 67: c. myc pathway.
Figure 68: Ras pathway.
Figure 69: Proto oncogene and oncogene.
Figure 70: Anti-oncogene.
Figure 71: Myc gene organization.
Figure 72: The FLT3 gene
Figure 73: Flt3 mutations.
Figure 74: Rb function.
Figure 75: P53 pathway

Chapter I: Eukaryotic Genetics Models

I. Introduction

Welcome to this captivating dive into the heart of eukaryotic genetic models, an educational odyssey illuminating five emblematic organisms. *Caenorhabditis elegans*, the elegant nematode, emerges as a translucent window into the intricate mechanisms of development and neurobiology. Endowed with a short life cycle and a fully sequenced genome, it provides an ideal model for comprehending the molecular intricacies underlying these fundamental processes.

Yeasts, particularly *Saccharomyces cerevisiae*, play an indispensable role in genetics as versatile unicellular models. Their genetic regulatory capabilities and ease of manipulation shed enlightening insights into various domains such as the cell cycle and metabolism, illustrating their importance in the genetic research landscape.

The fruit fly, the renowned "vinegar fly," with its short life cycle and ease of reproduction, remains a model of choice for its pioneering role in understanding embryonic development and genetic mechanisms. The fruits of these research endeavors continue to inspire the scientific community.

The mouse, as a mammalian model, offers crucial genetic proximity to humans, elevating biomedical research to significant heights. Its use in studying physiology and disease genetics provides valuable insights for the development of treatments and therapies.

Finally, plants, symbolized by *Arabidopsis thaliana*, unveil the richness of plant genetics, offering in-depth understanding of growth, stress response, and genetic regulation. Their complete sequencing has opened new avenues in research to enhance crop resilience.

This diverse exploration highlights the crucial importance of these models in our collective quest to understand complex genetic mechanisms. By embracing the diversity of organisms studied, we enrich our vision of eukaryotic genetics and broaden our capacity to address the scientific challenges of tomorrow.

II. Nematode *Caenorhabditis elegans*

II.1. Description

Caenorhabditis elegans, commonly abbreviated as *C. elegans*, stands as an exceptional biological model within the class of nematodes, boasting a diverse array of captivating biological attributes. Measuring approximately one millimeter in length, its remarkable transparency allows for intricate observations of internal structures, unveiling complex anatomy

despite its modest size (Figure 01). Its brief lifespan, with a complete cycle of about three days, provides valuable experimental flexibility for short-term studies, enabling swift exploration of various biological aspects.

C. elegans exhibits hermaphroditic reproduction, wherein a single individual can produce eggs through self-fertilization. However, under specific environmental conditions, males can also emerge. This mode of reproduction offers remarkable flexibility for studying genetics, development, and other biological processes. The ease of observing various stages of embryonic development, from fertilization to the formation of mature individuals, constitutes a major strength of *C. elegans* as a model organism.

The fully sequenced genome of *C. elegans* reveals a wealth of nearly 20,000 genes, many of which are conserved across more complex organisms, including humans. This genetic conservation makes it a particularly relevant model for understanding fundamental biological mechanisms and extrapolating study results from this nematode to other organisms, including mammals.

C. elegans has become a central player in developmental biology, cell biology, and neurobiology research. Its contributions extend beyond these areas to research on aging, stress responses, neurodegenerative diseases, and pharmacological interactions. Its ease of genetic manipulation and short life cycle (Figure 01) make it a versatile biological model, continuing to shed light on many facets of fundamental biology.




Figure 01: *Caenorhabditis elegans* life cycle

(<https://www.wormatlas.org/hermaphrodite/introduction/mainframe.htm>. Mise à jour

21/06/2024)

II.2. Genetics advantages:

The nematode *Caenorhabditis elegans* stands at the forefront of model organisms, playing a pivotal role in advancing molecular genetics and developmental biology. Its study has provided unparalleled insights into the intricacies of multicellular organism development, supported by compelling characteristics and quantifiable features:

II.2.1. Genome Simplicity and Cellular Consistency: *C. elegans* boasts a modest genome comprising approximately 20,000 genes, facilitating in-depth genetic analyses. The organism's remarkable consistency, with precisely 959 somatic cells in the hermaphrodite, allows for meticulous mapping and monitoring of cellular development.

II.2.2. Brief Life Cycle: With a remarkably short life span of two to three weeks, *C. elegans* enables accelerated experimentation and the swift observation of multiple generations, contributing to the efficiency and expediency of genetic studies.

II.2.3. Transparency for Microscopic Observations: The transparency of *C. elegans* has been a game-changer in developmental biology. This feature facilitates easy observation of organ and tissue development under a microscope, offering unprecedented visibility into internal processes.

II.2.4. Facile Genetics and Hermaphroditic Reproduction: The hermaphroditic nature of *C. elegans*, capable of self-fertilization, simplifies genetic studies. This unique feature streamlines the execution of genetic crosses and the investigation of hereditary trait transmission.

II.2.5. Reverse Genetics Applications: The technique of reverse genetics finds extensive application in *C. elegans* studies. This method allows researchers to perturb specific genes deliberately, providing insights into the regulatory pathways and mechanisms influencing organism development.

II.2.6. Gene Conservation and Evolutionary Significance: Many genes identified in *C. elegans* are evolutionarily conserved, underscoring the organism's relevance in understanding human genetics. Insights gained from studying these genes in *C. elegans* offer valuable information about their functions in human development.

II.2.7. Programmed Cell Death (Apoptosis) Studies: *C. elegans* has been instrumental in unraveling the mysteries of programmed cell death (apoptosis), a critical process in

multicellular organism development. Research involving *C. elegans* has led to seminal discoveries and a deeper understanding of apoptotic pathways.

The *C. elegans* serves as an indispensable model organism, combining genetic simplicity, rapid life cycle, transparency, and evolutionary conservation. The wealth of information gleaned from studying *C. elegans* has not only expanded our knowledge of fundamental biological processes but has also paved the way for groundbreaking discoveries with direct implications for human development and health.

II.3. Genetics description

In 1998, the nematode *Caenorhabditis elegans* made history as the first animal to have its entire genome sequenced, an accomplishment that provided an invaluable foundation for genetic and developmental biology research. The *C. elegans* genome consists of approximately 97 million base pairs and is organized into six pairs of chromosomes, characteristic of its diploid nature. Within this compact genome, scientists identified 19,099 genes, many of which have been conserved throughout evolution.

The discovery that about 40% of *C. elegans* genes have human homologs underscores the profound evolutionary and functional connections between this simple nematode and humans. This significant overlap in genetic makeup highlights the utility of *C. elegans* as a model organism, enabling researchers to explore fundamental biological processes that are relevant to human health and disease. These homologous genes include those involved in essential cellular functions such as development, metabolism, and apoptosis.

The evolutionary paths of *C. elegans* and humans diverged approximately 550 million years ago. Despite this vast evolutionary distance, *C. elegans* has retained many genes and pathways that are critical for basic biological functions, making it an excellent proxy for studying the complexities of more advanced organisms.

A notable aspect of *C. elegans* biology is its simplicity and transparency, which facilitate detailed studies of development and cellular processes. As a hermaphroditic species, it predominantly reproduces through self-fertilization, although males do exist and can contribute to genetic diversity through cross-fertilization. Its short lifecycle, comprising about three days from egg to adult, allows for rapid generation turnover and genetic studies.

The wealth of genomic information related to *C. elegans* is meticulously curated in WormBase, an extensive and publicly accessible online database. WormBase provides comprehensive annotations of the *C. elegans* genome, including gene functions, expression patterns, and

mutant phenotypes. This resource is invaluable for researchers worldwide, supporting a wide range of studies from basic genetics to complex systems biology.

Furthermore, the transparency of *C. elegans* allows for live-cell imaging of developmental processes, providing real-time insights into gene expression and function. The organism's invariant cell lineage, where the developmental fate of each cell is known and predictable, offers an unparalleled system for studying cell differentiation and organogenesis.

The sequencing of the *C. elegans* genome in 1998 was a groundbreaking achievement that has had lasting impacts on the field of genetics. With its well-annotated genome, evolutionary significance, and practical advantages as a model organism, *C. elegans* continues to be a cornerstone of genetic research, offering deep insights into the molecular underpinnings of life.

II.4. Cytogenetic and *C. elegans*

Holocentric chromosomes, first discovered in *Caenorhabditis elegans* (Figure 02), are characterized by centromeric activity distributed along their entire length rather than being confined to a single region. This unique chromosomal structure plays a crucial role during cell division, ensuring accurate chromosome segregation.




Figure 02: Holocentric chromosomes of *Caenorhabditis elegans*, DNA in red, kinetochores in green (Journal of Cell Biology (JCB)).

Unlike the more common monocentric chromosomes, which have a single centromere, holocentric chromosomes allow for multiple attachment points for spindle fibers. This can potentially reduce errors during mitosis and meiosis, as the forces are distributed along the entire length of the chromosome, minimizing the risk of nondisjunction or chromosome loss.

Studies in *C. elegans* have shown that microtubules attach along the entire length of the chromosome during cell division, ensuring an equitable distribution of chromosomes to daughter cells (Figure 03). This characteristic is particularly useful in cellular and molecular biology studies because it offers a simple and robust model for understanding the underlying mechanisms of chromosome segregation.




Figure 03: Representation of neocentromere and holocentromere on different cycle of mitosis (from [Frontiers in Plant Science](#)).

Using *C. elegans* to study holocentric chromosomes has provided significant insights into how these unique structures influence chromosomal stability and the fidelity of cell division. Additionally, this research has important implications for other eukaryotes that also possess holocentric chromosomes, such as certain plants, insects, and other nematodes.

The discovery of holocentric chromosomes in *C. elegans* has not only enriched our understanding of chromosomal architectural diversity but also provided a valuable model for exploring chromosome segregation mechanisms across a wide range of eukaryotic organisms.

II.5. Longevity Genetic markers and *C. elegans*

a. The aging alteration protein 1 (Age-1) marker

The process of inducing mutations in *Caenorhabditis elegans* using Ethyl Methane Sulfonate (EMS) led to a significant breakthrough in the study of aging (Figure 04). EMS, a

powerful chemical mutagen, was used to generate random genetic mutations in the nematode population. Through this method, researchers isolated the first five mutants that exhibited a remarkable increase in lifespan compared to the wild-type worms.




Figure 04: Representation of the age experience (consult [Jorgensen and Mango \(2002\)](#)).

Detailed genetic mapping of these longevity mutants revealed that four out of the five had alterations in the same genetic locus, identified as *age-1*. The *age-1* gene encodes a protein known as aging alteration protein 1, which plays a critical role in the regulation of the organism's lifespan. The identification of this locus was a pivotal moment, as it provided direct evidence that mutations in a single gene could extend the life of an organism.

Further studies on the *age-1* mutants demonstrated that the increased longevity was not the only beneficial effect. The appearance of aging markers, such as reduced movement, decreased reproduction rates, and visible signs of aging, was also delayed in these mutants. This delay suggested that the *age-1* mutation not only extended lifespan but also improved overall health during the extended lifespan, a concept referred to as "healthspan."

The discovery of the *age-1* gene and its role in longevity had profound implications. It suggested that the mechanisms of aging could be manipulated at the genetic level, opening up possibilities for understanding the fundamental processes of aging and for developing interventions to promote longer, healthier lives in other organisms, including humans. The *age-1* gene became a focal point for further research into the molecular pathways that control aging, particularly those involving insulin/IGF-1 signaling, which was later found to be a significant pathway in the regulation of lifespan across multiple species.

The use of EMS in *C. elegans* led to the isolation of longevity mutants, the discovery of the age-1 gene, and significant insights into the genetic regulation of aging. This research highlighted the potential for genetic interventions to extend lifespan and improve health during aging, making it a cornerstone of modern gerontology and molecular biology.

b. The dauer abnormal formation protein 2 marker (Daf-2)

In 1993, Kenyon and her team made a significant breakthrough by identifying the *daf-2* gene, also known as dauer abnormal formation protein 2, in the roundworm *Caenorhabditis elegans* (Figure 05). They found that deleting this gene resulted in remarkable increases in the worm's lifespan and decelerated the aging process. Additionally, mutations in *daf-2* and *age-1* were found to facilitate the transition of larvae into the dauer stage, a resilient developmental state assumed by the worm in response to unfavorable environmental conditions.




Figure 05: The dauer abnormal formation protein 2 marker on life cycle of *c. Elgans* ([Ngoc Minh Ha et al. 2022](#))

Further studies revealed that mutations in the *daf-16* gene, which encodes a FOXO family transcription factor, actually reduced the lifespan of the worms. This suggests that DAF-16 plays a crucial role in promoting longevity and modulating the effects of *daf-2* and *age-1* mutations.

The subsequent cloning and sequencing of AGE-1, DAF-2, and DAF-16 genes allowed scientists to uncover the functions of the proteins they encode. For instance, AGE-1 encodes the catalytic subunit p110 of phosphatidylinositol 3-kinase (PI3K), while DAF-2 encodes the insulin receptor and insulin-like growth factor-1 receptor (IR/IGF-1R), and DAF-16 encodes a FOXO family transcription factor (Figure 06).




Figure 06: The impact of AGE-1 and DAF-2 on DNA (license: [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/)).

AGE-1 and DAF-2 are integral components of the insulin and insulin-like growth factor-1 (IGF-1) signaling pathway. This pathway is known to regulate various cellular processes, including metabolism, growth, and longevity. The intricate interplay between these genes and their corresponding proteins provides valuable insights into the mechanisms governing aging and lifespan regulation.

Moreover, the groundbreaking discoveries made in *C. elegans* have implications beyond this species. Studies have confirmed the acceleration of aging in other organisms, such as yeast (via the G protein-coupled receptor 1 glucose receptor), fruit flies, and mice, emphasizing the evolutionary conservation of aging pathways.

These findings not only deepen our understanding of the fundamental mechanisms of aging but also hold promise for potential interventions to extend lifespan and mitigate age-related diseases in humans and other organisms.

In addition to genetic factors, environmental influences such as diet also play a significant role in modulating lifespan in *C. elegans*. Caloric restriction, a well-studied phenomenon in aging research, has been shown to dramatically extend the lifespan of non-mutant worms when implemented in their culture media. This suggests that dietary interventions can have profound effects on longevity.

Conversely, diets rich in nutrients, particularly glucose, have been found to accelerate the aging process in *C. elegans*. This underscores the importance of nutrient balance and metabolic regulation in determining lifespan.

The signaling pathway involving DAF-2, the insulin/IGF-1 receptor, is crucial in mediating the effects of dietary changes on aging. Specifically, when worms are subjected to certain caloric restriction conditions, the activity of the DAF-2 pathway is repressed. This repression likely contributes to the observed increase in lifespan under caloric restriction.

These findings highlight the intricate interplay between genetics, diet, and signaling pathways in regulating aging and lifespan in *C. elegans* (Figure 07). Understanding these interactions not only sheds light on the fundamental mechanisms of aging but also holds promise for identifying strategies to promote healthy aging and longevity in humans.




Figure 07: The interaction between genetics, diet, and signaling pathways in regulating aging and lifespan in *C. elegans*.

II.6. The epigenetic and *C. elegans*

In 2017, Klosin and colleagues conducted a groundbreaking study that illuminated the intricate role of epigenetics in aging and longevity in *C. elegans* (Figure 08). They discovered that thermal stress has the remarkable ability to induce the expression of previously repressed copies of genes, particularly those considered non-coding or "junk DNA," within the worms. This effect persisted across at least 14 generations, highlighting the transgenerational impact of environmental stressors on gene expression.





Figure 08: The acetylation, methylation and phosphorylation of histone (uploaded by [Danny Reinberg](#))

At the molecular level, chromatin modifications occur early in embryogenesis, even before the onset of transcription. These modifications are not only inherited but also profoundly influence gene expression patterns throughout the lifespan of the organism. Specifically, alterations in the trimethylation status of histone H3 at lysine 9 (H3K9me3) have been implicated in aging. Conversely, the trimethylation of histone H3 at lysine 4 (H3K4me3) increases with age, and interventions that prevent or demethylate this protein have been shown to extend longevity in *C. elegans* (Figure 09).



Interestingly, increased levels of H3K27me3 have been associated with longevity in worms. However, the demethylation of H3K27, facilitated by the demethylase UTX-1 (ubiquitously transcribed TPR on X-1), leads to the upregulation of daf-2 expression, ultimately accelerating the aging process in *C. elegans*.

These findings underscore the dynamic interplay between epigenetic modifications, environmental stimuli, and genetic pathways in shaping the aging process. By elucidating the epigenetic mechanisms underlying longevity, researchers gain insights into potential targets for therapeutic interventions aimed at promoting healthy aging and extending lifespan in humans.

a. Histone code

Histone modifications, occurring predominantly on the tails of histone proteins, are essential epigenetic marks that regulate chromatin structure and gene expression. These modifications include methylation, acetylation, phosphorylation, ubiquitination, sumoylation, and ADP-ribosylation, among others. The diverse array of histone modifications and their combinatorial patterns have led to the proposal of the "histone code" hypothesis (Figure 10).




Figure 10: Histone code ([Brian D. Strahl](#) et al 2000).

The histone code hypothesis posits that specific combinations of histone modifications serve as a regulatory language, dictating chromatin dynamics and gene activity. This concept suggests that different combinations of modifications create distinct chromatin states that are interpreted by protein complexes, termed "readers," to elicit specific downstream effects. These readers

recognize and bind to modified histones, thereby recruiting additional chromatin-modifying enzymes or transcriptional regulators to modulate gene expression.

For instance, histone acetylation, catalyzed by histone acetyltransferases (HATs), generally correlates with transcriptional activation by neutralizing the positive charge of histones and loosening chromatin structure. Conversely, histone methylation, catalyzed by histone methyltransferases (HMTs), can either activate or repress gene expression, depending on the specific lysine or arginine residues targeted and the degree of methylation (mono-, di-, or trimethylation). Phosphorylation of histones by kinases can also influence chromatin structure and transcriptional activity by altering histone-DNA interactions.

Furthermore, the histone code is dynamic and responsive to various cellular signals and environmental cues. For example, exposure to stressors such as heat shock can induce changes in histone modifications, leading to altered gene expression patterns. Additionally, the inheritance of histone modifications through cell divisions suggests a role in epigenetic memory and cellular identity maintenance.

The concept of the histone code provides a framework for understanding the complex interplay between chromatin structure, histone modifications, and gene regulation. Deciphering the histone code is crucial for unraveling the molecular mechanisms underlying development, differentiation, and disease, as well as for identifying potential therapeutic targets for epigenetic-based therapies.

II.7. The *RNAi* and *C. elegans*

In *C. elegans*, there is a direct link between histone modifications and longevity, as observed through research. To further investigate this relationship, screens using RNA interference (RNAi) have been conducted (Figure 11). RNAi is a natural biological process that regulates gene expression by using small pieces of RNA to interact with messenger RNA (mRNA) molecules, thereby suppressing or inhibiting their translation into proteins.




Figure 11: Regulation of RNAi (<https://www.umassmed.edu/rti/biology/rna/how-rnai-works/>).

21/11/2024)

Specifically, in *C. elegans*, RNAi screens targeting genes encoding methyltransferases and demethylases have shed light on their role in controlling the worm's longevity. Inhibition of the expression of genes such as *ash-2*, *set-9*, *set-15*, *set-26* (methyltransferases), *mes-2*, *jmjd-2*, *lsd-1*, and *utx-1* (demethylases) has been shown to influence the lifespan of the worm. This suggests that the activity of these enzymes, which regulate histone modifications, plays a crucial role in determining longevity in *C. elegans*.

This connection underscores the intricate regulatory network governing aging and lifespan, where epigenetic modifications, such as histone methylation and demethylation, exert profound effects on gene expression and cellular processes. Understanding these mechanisms not only enhances our knowledge of aging biology but also holds promise for identifying potential targets for interventions aimed at promoting healthy aging and extending lifespan in organisms, including humans.

Additionally, it's worth noting that RNAi has diverse roles beyond regulating gene expression in aging (Figure 12). In plants, for instance, small interfering RNA (siRNA) can prevent the multiplication of viral RNA, highlighting the versatility of RNAi across different biological contexts.




Figure 12: The interaction between genetics, diet, signaling and stress pathways in regulating aging and lifespan in *C. elegans*.

II.8. The *miRNA* and *C. elegans*

In *C. elegans*, non-coding RNAs, particularly microRNAs (miRNAs) (Figure 13), have emerged as key regulators of various biological processes, including longevity. These small RNA molecules, expressed by the worm, exert their influence by modulating the expression of target genes, ultimately impacting lifespan.

Studies have revealed a nuanced relationship between specific miRNAs and longevity in *C. elegans*. For instance, *mir-239* has been found to accelerate aging in the worm, while *mir-71*, *mir-228*, and *mir-246* promote longevity. These miRNAs play multifaceted roles, including regulating the response to environmental stressors such as thermal stress.




Figure 13: Representation of mi RNA by [\(Mariano J. Scian\)](#)

miRNAs were initially discovered in *C. elegans*, and much of our understanding of miRNA biology and their targets has been derived from studies in this organism. *C. elegans* possesses over 200 miRNAs, providing a rich resource for investigating their functions and regulatory networks. While humans have over 1000 miRNAs, the foundational work on miRNAs in *C. elegans* has laid the groundwork for understanding their roles in other organisms.

The discovery of miRNAs and their resemblance to small interfering RNAs (siRNAs) has revolutionized our understanding of genetic regulation. For example, the *lin-4* gene in *C. elegans* encodes a small RNA molecule that undergoes processing to produce a 22nt miRNA. This miRNA regulates the expression of its target gene, *lin-14*, by binding to specific sequences in the 3' untranslated region (UTR) of *lin-14* mRNA. Consequently, the expression of *lin-14* protein is reduced upon *lin-4* expression, illustrating the regulatory role of miRNAs in controlling gene expression.

Overall, the intricate interplay between miRNAs and their target genes in *C. elegans* provides valuable insights into the molecular mechanisms underlying longevity and other biological processes. Understanding these regulatory networks not only advances our knowledge of basic biology but also holds potential for therapeutic interventions targeting age-related diseases in humans.

II.9. Limits of *C. elegans* model

While *Caenorhabditis elegans* (*C. elegans*) serves as an invaluable model organism for studying various biological processes, there are inherent limitations to its utility in addressing certain complex biological questions and translating findings to human clinical applications.

Firstly, despite its genetic tractability and amenability to experimental manipulation, *C. elegans* is evolutionarily distant from humans (Figure 14). This evolutionary gap means that certain aspects of physiology, development, and disease biology in humans may not be accurately recapitulated in *C. elegans*. Therefore, findings from studies in *C. elegans* may not always directly apply to humans.




Figure 14: Phylogenetic tree of *C. elegans* (Available via license: [CC0](https://creativecommons.org/licenses/by/4.0/))

Secondly, the anatomical simplicity of *C. elegans* presents a significant limitation. Unlike mammals, *C. elegans* lacks internal organs such as lungs, kidneys, or a liver. As a result, it is challenging to study complex interactions between different organ systems or model diseases that specifically affect these organs. For instance, research on diseases like lung cancer or renal failure may be limited due to the absence of these organs in *C. elegans*.

Moreover, while discoveries made in *C. elegans* have led to significant insights into fundamental biological processes, their translation into clinical applications for human health can be challenging. The biological differences between *C. elegans* and humans mean that findings in this organism may not always directly inform therapeutic strategies or drug development for human diseases.

Overall, while *C. elegans* remains a powerful model organism for studying a wide range of biological phenomena, researchers must be mindful of its limitations. Integrating findings from *C. elegans* with data from other model systems and human studies is essential for gaining a comprehensive understanding of complex biological processes and developing clinically relevant interventions.

III. Yeasts

III.1. Description

Yeast, particularly the species *Saccharomyces cerevisiae*, has long served as a model organism for studying eukaryotic biology due to its ease of cultivation, rapid growth rate, well-

characterized genetics, and evolutionary conservation with higher eukaryotes. Here's a description of yeast as a model eukaryote:

1. **Genetic tractability:** Yeast has a compact genome that is easily manipulated, facilitating the study of gene function, regulation, and interactions. Its genome is well-annotated, with many genes having known functions and orthologs in higher eukaryotes.
2. **Simple eukaryotic structure:** While yeast is a eukaryote, its cellular structure is relatively simple compared to multicellular organisms, making it easier to study fundamental cellular processes. Yeast cells contain membrane-bound organelles such as the nucleus, endoplasmic reticulum, Golgi apparatus, and mitochondria, allowing researchers to investigate intracellular dynamics and organelle function (Figure 15).
3. **Conservation of cellular processes:** Many cellular processes and molecular pathways are highly conserved between yeast and higher eukaryotes, including humans. This conservation allows researchers to study fundamental biological processes such as cell cycle regulation, DNA replication, transcription, translation, and signal transduction in a simplified system.
4. **Model for disease research:** Yeast has been instrumental in studying the molecular mechanisms underlying various human diseases, including neurodegenerative disorders, cancer, and infectious diseases. Yeast models can be used to screen for potential drug candidates, elucidate disease mechanisms, and identify genetic modifiers of disease phenotypes.
5. **Biotechnological applications:** Yeast has numerous industrial applications, particularly in the field of biotechnology. *Saccharomyces cerevisiae*, for example, is used in the production of bread, beer, wine, and biofuels due to its ability to ferment sugars into ethanol and carbon dioxide. The genetic tractability of yeast also makes it a valuable tool for engineering strains with improved traits for industrial processes.




Figure 15: Test cell structure (<https://www.istockphoto.com/illustrations/yeast-cells>. Mise à jour 24-06-2024)

Yeast serves as an excellent model organism for studying fundamental biological processes, elucidating disease mechanisms, and developing biotechnological applications. Its simplicity, genetic tractability, and evolutionary conservation make it a versatile and powerful system for scientific research.

III.2. Genetics advantages

The yeast, particularly *Saccharomyces cerevisiae*, offers several genetic advantages that make it an exceptional model organism for genetic research:

1. **Haploid and diploid phases:** Yeast has both haploid and diploid phases in its life cycle, allowing for the study of genetic interactions and processes such as mating, meiosis, and sporulation. The ability to manipulate both haploid and diploid yeast strains facilitates the investigation of recessive mutations, gene complementation, and genetic crosses.
2. **Short generation time:** Yeast has a rapid growth rate and short generation time, with a typical doubling time of about 90 minutes under optimal conditions. This rapid

proliferation enables researchers to perform experiments and genetic crosses quickly, accelerating the pace of genetic research.

3. **Small genome size:** The genome of *Saccharomyces cerevisiae* is relatively small (~12 million base pairs) compared to other eukaryotes, making it more manageable for genetic analysis. The compact genome simplifies sequencing, gene mapping, and the identification of mutations, facilitating the study of gene function and regulation.
4. **Ease of genetic manipulation:** Yeast is amenable to various genetic manipulation techniques, including gene knockout, gene overexpression, gene tagging, and site-directed mutagenesis. These techniques allow researchers to precisely manipulate the yeast genome to study the effects of specific genetic alterations on cellular processes.
5. **Homologous recombination:** Yeast exhibits high rates of homologous recombination, which enables efficient gene targeting and gene replacement. This feature is particularly advantageous for generating precise genetic modifications and studying the function of specific genes.
6. **Comprehensive genetic tools:** Yeast has a well-developed toolkit of genetic and molecular biology techniques, including plasmid vectors, selectable markers, gene expression systems, and genome editing tools such as CRISPR-Cas9. These tools facilitate the manipulation, analysis, and visualization of yeast genes and gene products.
7. **Conservation of genetic pathways:** Many essential genetic pathways and processes are highly conserved between yeast and higher eukaryotes, including humans. Studying these pathways in yeast provides insights into fundamental biological processes and disease mechanisms that are applicable to other organisms.

The genetic advantages of yeast make it a powerful model organism for elucidating gene function, understanding genetic interactions, and uncovering the molecular mechanisms underlying various biological processes. These characteristics have contributed to yeast's widespread use as a model system in genetics research.

III.3. Genetics description

The genetic description of yeast, particularly *Saccharomyces cerevisiae*, has undergone significant advancements since the sequencing of the S288C strain in 1996. This landmark achievement, coordinated by sixteen geneticists under the supervision of André Goffeau, involved the collaboration of 641 scientists from 96 laboratories worldwide. The S288C strain

revealed a genome consisting of 16 chromosomes, with a total of 12 million base pairs encoding approximately 6,572 genes. Remarkably, about 23% of yeast genes were found to have similarities with the human genome, highlighting the evolutionary conservation of genetic pathways between yeast and higher eukaryotes. Subsequent efforts, such as the Fungal Genomes Project initiated in 2011, further expanded our understanding of yeast genetics by decoding the genomes of numerous yeast strains from diverse origins. By 2018, over 800 yeast genomes had been sequenced, providing valuable insights into genetic diversity and evolutionary relationships within the *Saccharomyces* genus. Additionally, resources like the *Saccharomyces* Genome Database have played a pivotal role in cataloging and annotating yeast genes, facilitating research in genetics and molecular biology. These genetic descriptions have laid the foundation for comprehensive studies of gene function, regulation, and evolution in yeast, making it a premier model organism for genetic research.

III.4. The cystathionine beta-synthase (CBS) and yeast model

The relationship between yeast and CBS (cystathionine beta-synthase) lies in their homologous genes and the utility of yeast as a model system to study CBS-related disorders.

The gene encoding cystathionine beta-synthase (CBS) in humans is associated with the production of the CBS protein, which plays a crucial role in sulfur metabolism, specifically in the transsulfuration pathway (Figure 16). Mutations in the CBS gene can lead to a metabolic disorder known as homocystinuria, characterized by elevated levels of homocysteine in the blood. This condition can result in various clinical manifestations, including intellectual disability, skeletal abnormalities, lens dislocation, and premature atherosclerosis.




Figure 16: The cystathionine beta-synthase (CBS) cycle (Duaa W. Al-Sadeq et al., 2020).

In yeast, the homologous gene to human CBS is *CYS4*, which also codes for a cystathionine beta-synthase protein. Researchers have utilized yeast models with mutations in the *CYS4* gene to mimic aspects of homocystinuria and study the underlying molecular mechanisms. By inactivating the *CYS4* gene in yeast, researchers can investigate the effects of CBS deficiency on cellular metabolism, growth, and viability. This approach provides valuable insights into the pathophysiology of homocystinuria and facilitates the screening of potential therapeutic interventions.

The homology between CBS in humans and *CYS4* in yeast allows for comparative studies to elucidate conserved molecular pathways and functional domains. By leveraging the genetic tractability and experimental advantages of yeast, researchers can gain a deeper understanding of CBS-related disorders and explore novel strategies for diagnosis and treatment. Overall, the relationship between yeast and CBS underscores the utility of yeast as a model organism to investigate human genetic diseases and identify therapeutic targets.

III.5. Functional Analysis of Separated Alleles in Yeast (FASAY)

Functional Analysis of Separated Alleles in Yeast (FASAY) is a genetic approach utilized to investigate the functional consequences of specific mutations in genes, particularly those implicated in human diseases. This method capitalizes on the conservation of gene function between yeast and humans, enabling researchers to explore the effects of mutations in yeast orthologs of human genes (Figure 17).




Figure 17: Model of human model with and without yeast homologue using FASAY

(uploaded by [Samuele Lodovichi](#)).

In FASAY, the gene under scrutiny is integrated into a yeast strain lacking its native counterpart (null mutant). Subsequently, two versions of the gene are introduced separately into the yeast strain: one harboring the wild-type allele and the other containing the mutant allele. This procedure generates two distinct yeast strains, each expressing either the wild-type or mutant allele of the gene.

These yeast strains undergo various assays to evaluate the functional consequences of the mutant allele. Growth assays, for instance, compare the growth rates of yeast strains expressing the wild-type and mutant alleles under diverse conditions, such as fluctuating nutrient availability or exposure to stressors. Furthermore, biochemical assays can gauge the activity of the gene product or its downstream targets in yeast cells expressing the wild-type or mutant allele.

FASAY offers insights into how specific mutations in genes impact their function and contribute to disease phenotypes. When studying genes with yeast orthologs, this approach elucidates the molecular mechanisms underlying human diseases. However, in cases where there is no yeast homolog, FASAY cannot be employed to directly assess the effects of mutations. In such instances, alternative methods, such as cell culture models or animal models, may be utilized to explore the functional consequences of mutations in the human gene.

III.6. The Functional Impact of P53 Hotspot Mutations, p63, and p73 in Yeast Using FASAY

In this comprehensive experimentation employing the Functional Analysis of Separated Alleles in Yeast (FASAY) model, the primary objective is to delve into the functional consequences of specific mutations in the P53 gene, along with the related genes p63 and p73 (Figure 18). These genes play pivotal roles in regulating critical cellular processes, particularly in the context of cancer development. By utilizing yeast as a model system, researchers can gain valuable insights into the functional implications of these mutations and their potential contributions to tumorigenesis.




Figure 18: Representation of p53, p63 and p73 genetic organization (Upload by oncogene).

Furthermore, this study explores the role of yeast models in elucidating the molecular mechanisms underlying prion diseases, a group of neurodegenerative disorders characterized by the misfolding of the normal prion protein (PrPC) into its pathogenic form (PrPSc) (Figure 19). These diseases give rise to several lethal and transmissible conditions in humans and other animals. Despite extensive research, the precise factors triggering protein misfolding and the infectious properties of the abnormal protein structure remain elusive.




Figure 19: Normal prion protein (PrPC) and pathogenic form (PrPSc) (uploaded by [Sarman Singh](#)).

The experimentation not only investigates the consequences of P53 mutations but also sheds light on the crucial role of chaperone proteins, particularly Heat Shock Proteins (Hsps), in mitigating protein misfolding and aggregation. Chaperones such as Hsps play essential roles in protein quality control by assisting in the proper folding (Figure 20), maturation, and stabilization of proteins. They act as guardians against protein misfolding and aggregation, thus preventing the onset of neurodegenerative diseases and other proteinopathies.




Figure 20: Roles of chaperones Hsps. Upload by cell system.

Through this multidimensional study, researchers aim to unravel the intricate interplay between genetic mutations, protein misfolding, and disease pathology. By leveraging the genetic tractability and experimental advantages of yeast, this research endeavor holds the potential to uncover novel therapeutic targets and intervention strategies for cancer and neurodegenerative disorders.

III.7. The pathogenic effects of mutated α -synuclein and huntingtin proteins in yeast models

The investigating the Pathogenic Effects of Mutated α -Synuclein and Huntingtin Proteins in Yeast Models: Insights into Parkinson's Disease and Huntington's Disease Pathology. In this experimental investigation utilizing yeast models, the focus is on elucidating the pathogenic effects of mutated α -synuclein and huntingtin proteins, which are implicated in Parkinson's disease and Huntington's disease, respectively. By introducing mutated forms of these proteins into yeast cells, researchers aim to mimic the pathological conditions observed in these neurodegenerative disorders and study the underlying molecular mechanisms.

α -Synuclein is associated with Parkinson's disease, a progressive neurodegenerative disorder characterized by the accumulation of Lewy bodies in the brain. Mutations in the α -synuclein gene lead to aberrant protein aggregation, neuronal dysfunction, and ultimately, neurodegeneration. By expressing mutated α -synuclein in yeast models, researchers can investigate the cytotoxic effects of protein aggregation and explore potential therapeutic interventions.

Similarly, huntingtin protein, encoded by the HTT gene, is implicated in Huntington's disease, an inherited neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. Mutated huntingtin proteins contain an expanded polyglutamine tract, leading to protein misfolding, aggregation, and neuronal toxicity. Yeast models expressing mutated huntingtin proteins provide a platform to study the cellular consequences of protein misfolding and elucidate disease mechanisms.

Furthermore, this experimentation aims to explore the role of kynurenine 2,3-monooxygenase (KMO), an enzyme involved in the metabolism of tryptophan along the kynurenine pathway. Dysregulation of KMO activity has been implicated in neurodegenerative diseases, including Parkinson's and Huntington's diseases. By manipulating KMO expression in yeast models,

researchers can investigate its impact on disease pathology and identify potential therapeutic targets for intervention.

Through this multifaceted approach, researchers seek to gain valuable insights into the molecular mechanisms underlying Parkinson's disease and Huntington's disease pathology. By leveraging the genetic tractability and experimental advantages of yeast models, this research endeavor holds the potential to uncover novel therapeutic strategies for the treatment of these devastating neurodegenerative disorders.

III.8. The Epstein-Barr Virus (EBV)-Related Tumors in Yeast Models

In this experimental inquiry employing yeast models, the focus is on elucidating the mechanisms underlying virus-induced cancers, exemplified by Epstein-Barr virus (EBV)-associated malignancies. EBV, a member of the herpesvirus family, has been implicated in various cancers, including lymphomas and nasopharyngeal carcinoma. One of the key proteins involved in EBV-associated tumorigenesis is EBNA1, which plays a critical role in maintaining viral genome stability and replication. Notably, EBNA1 is tightly regulated to evade detection by the immune system, allowing EBV-infected cells to proliferate unchecked.

The central concept of this investigation is to disrupt the tight control of EBNA1 levels within tumor cells, thereby exposing them to the immune system for recognition and elimination. By manipulating EBNA1 expression in yeast models, researchers aim to unravel the molecular mechanisms underlying immune evasion in EBV-related cancers. Through innovative approaches, such as modulating the expression of nucleolar proteins involved in EBNA1 regulation, researchers seek to interfere with this immune evasion strategy and sensitize tumor cells to immune surveillance.

Furthermore, this study explores the potential of yeast models as a platform for screening novel immunotherapeutic strategies targeting EBV-associated tumors. By leveraging the genetic tractability and experimental advantages of yeast, researchers can gain valuable insights into the intricate interplay between viral oncogenesis and immune evasion mechanisms. Ultimately, this research endeavor holds promise for the development of innovative immunotherapeutic approaches aimed at combating EBV-related cancers and improving patient outcomes.

II.9. Limits of yeast model

Despite its widespread use as a model organism, leveraging yeast models for biomedical research faces several limitations due to fundamental organismal differences between yeast and humans. Yeast, being a unicellular organism, lacks the intricate multicellular organization and

biological complexity characteristic of humans. Additionally, yeast lacks specific tissues and organs present in humans, limiting the scope of studies on organ-specific diseases or interactions between different organ systems. Furthermore, differences in genes and metabolic pathways between yeast and humans pose challenges in extrapolating findings from yeast models to human biology accurately. The complexity of human physiology far exceeds that of yeast, with biological processes in humans being highly regulated and context-dependent. Moreover, the absence of an immune system in yeast complicates the study of immune-related diseases and therapies, which are integral aspects of human health. Despite these limitations, innovative approaches integrating findings from yeast models with data from other model organisms and human studies can help bridge the gap between yeast research and human biology, enabling more comprehensive insights into disease mechanisms and therapeutic interventions.

IV. Drosophile *Drosophila melanogaster*

IV.1. Description

Drosophila melanogaster, commonly known as the fruit fly, is a widely utilized model organism in biological research due to its relevance to understanding eukaryotic cell biology. Morgan et al (Figure 21) his began using mutants to provide experimental evidence for the chromosomal theory of inheritance, and they devised genetic mapping methods that are still in use today.




Figure 21: Picture of Thomas Hunt Morgan.

This tiny insect offers researchers numerous advantages for studying cellular processes. One key advantage is its evolutionary conservation with humans, sharing many fundamental cellular mechanisms such as cell cycle regulation, signal transduction pathways, and developmental processes. This evolutionary similarity allows findings from fruit fly research to be extrapolated to higher organisms, including humans. Additionally, *Drosophila* possesses a short life cycle and produces a large number of offspring, facilitating genetic studies and the generation of mutant strains for functional analysis. Its genetic tractability is further enhanced by well-established genetic tools like transgenic techniques, RNA interference (RNAi), and CRISPR/Cas9 genome editing, enabling precise manipulation of gene expression and function. Moreover, the small size and transparency of *Drosophila* embryos enable researchers to conduct live imaging studies, providing insights into dynamic cellular processes in real-time. Overall, *Drosophila melanogaster* serves as a highly valuable model system for unraveling the intricacies of eukaryotic cell biology and its implications for human health and disease.

IV.2. Genetics advantages

Drosophila melanogaster stands as a cornerstone model organism in developmental biology and genetics, owing to a plethora of advantageous traits:

- **Small and Easy to Rear:** *Drosophila melanogaster*'s compact size and ease of maintenance in laboratory conditions make it a convenient model organism for experimental studies.
- **Short Generation Cycle:** With a brief generation cycle lasting approximately two weeks (Figure 22), *Drosophila* allows for rapid experimental turnover and efficient generation of experimental populations.




Figure 22: *Drosophila melanogaster*'s life cycle (<https://www.walter-lab.com/methods>. Misr à jour 24/06/2024).

- **High Productivity:** Female *Drosophila* possess the remarkable ability to lay up to 500 eggs in just ten days, ensuring a plentiful supply of experimental subjects for genetic and developmental studies.
- **Simplified Genetic Studies:** The absence of recombination in male *Drosophila* simplifies genetic studies, allowing researchers to more easily trace the inheritance patterns of traits and manipulate genes of interest.
- **Genetic Transformation Techniques:** Since 1987, genetic transformation techniques have been available for *Drosophila melanogaster*, enabling researchers to introduce foreign DNA into the fly genome with precision, facilitating the study of gene function and regulation.

IV.3. Genetics description

Drosophila melanogaster, renowned for its pivotal role in genetic research, boasts a genome structure of remarkable simplicity. Comprising only four pairs of chromosomes - three autosomes (designated as 2, 3, and 4) and a single sex chromosome pair (X/Y) - the fruit fly's genome spans approximately 165 million base pairs and houses around 13,000 genes. This compact genome was meticulously sequenced and annotated in 2000, marking a significant milestone in genetic research.

The sequencing of the *Drosophila* genome not only provided insights into its genetic makeup but also revealed striking parallels with the human genome. Comparative genomic analyses have shown that 60% of *Drosophila* genes are conserved in humans, highlighting the evolutionary conservation of genetic pathways and processes across species. Furthermore, a comprehensive analysis in 2001 revealed that an impressive 77% of genes associated with identified human diseases have homologues in the *Drosophila* genome. This genetic similarity has positioned *Drosophila* as a powerful model for investigating various human diseases, including neurodegenerative disorders like Parkinson's disease and Huntington's disease.

The genetic tractability of *Drosophila*, coupled with its well-characterized genome and sophisticated genetic tools, has revolutionized genetic research. The fruit fly's amenability to genetic manipulation, rapid generation time, and high reproductive capacity make it an ideal model for elucidating gene function, regulatory mechanisms, and disease pathogenesis. By leveraging the genetic resources available for *Drosophila* research, scientists can conduct

targeted genetic screens, gene knockdown experiments, and genome-wide association studies to dissect complex biological processes and identify novel therapeutic targets.

Drosophila melanogaster's genetic simplicity, coupled with its evolutionary conservation and experimental versatility, has solidified its status as an indispensable model organism for advancing our understanding of fundamental biological principles and unraveling the genetic basis of human health and disease.

IV.4. Polytene chromosome

Polytene chromosomes, a distinct chromosomal configuration observed in specific cells of organisms like *Drosophila* (fruit flies), result from a process called polytenization (Figure 23). During this phenomenon, chromatid strands align and replicate repeatedly without separation, leading to elongated chromosomes with characteristic banding patterns. These structures have become indispensable in genetic studies, particularly in *Drosophila* research, where they serve as vital tools for gene mapping, mutation analysis, and understanding chromosomal architecture. By exploiting the prominent banding patterns on polytene chromosomes, researchers can precisely locate genes and genetic elements along the chromosome, aiding in the identification of gene functions and regulatory regions. Additionally, the exceptional resolution of polytene chromosomes, with each band representing approximately 20 kilobases of DNA, allows for detailed exploration of chromosomal organization, including the investigation of structural variations and their impact on gene expression and genome function.




Figure 23: Polytene chromosome. *Journal of Heredity* 25: 465–47.

In essence, polytene chromosomes in *Drosophila* provide a rich resource for dissecting the genetic basis of traits and diseases, offering insights into fundamental biological processes.

IV.5. The puffs

In *Drosophila* research, puffs denote specific regions observed on polytene chromosomes (Figure 24), distinguished by the relaxation of chromatin. These areas act as

visual cues for active genetic transcription, signifying where DNA undergoes transcription into RNA molecules, crucial for subsequent protein synthesis. Puffs serve as pivotal tools for delving into genetic regulation and transcription dynamics within *Drosophila* cells. They play a vital role in mapping active genes and unraveling the intricate mechanisms dictating gene expression.




Figure 24: The puffs specific regions observed on polytene chromosomes (uploaded by Igor F Zhimulev)

Through the study of puffs, researchers gain valuable insights into the nuanced processes governing transcriptional activity, shedding light on how genes are precisely regulated in response to various internal and external stimuli. Ultimately, the exploration of puffs in *Drosophila* contributes significantly to our broader comprehension of genetic regulation and cellular function.

IV.6. The P element

The P elements, compact DNA sequences measuring 2.9 kilobases and featuring four exons (Figure 25), constitute a significant element in *Drosophila* research.




Figure 25: Genetic organization of P element (Chapter 26 - Lipids and Lipid Signaling in *Drosophila* Models of Neurodegenerative Diseases).

In germ cells, they showcase active transposase activity, facilitating their mobility within the genome. However, in somatic cells, a truncated version of the transposase protein acts as a suppressor, mitigating their transpositional activity. Leveraging P elements in *Drosophila* has revolutionized genetic manipulation techniques. Through mutagenesis approaches such as insertion, deletion, and overexpression, researchers can precisely manipulate the fly genome, unraveling the intricacies of gene function and regulation. Techniques like RNA interference (RNAi) further enable the selective suppression of gene expression, offering insights into gene function and pathway elucidation. Additionally, the GAL4/UAS system provides a sophisticated tool for spatial and temporal control of transgene expression, facilitating the interrogation of gene function in a highly targeted manner. Overall, the versatile applications of P elements in *Drosophila* research underscore their pivotal role in genetic manipulation and regulatory studies, advancing our understanding of fundamental biological processes.

IV.7. The Balancer chromosome

Balancer chromosomes, intricately engineered constructs, play a pivotal role in genetic studies, especially in model organisms like *Drosophila melanogaster*. These specialized chromosomes are designed to carry specific genetic modifications, such as chromosomal inversions, duplications, or rearrangements, which confer unique properties that facilitate their use in various genetic experiments. One of the primary functions of balancer chromosomes is

to maintain specific genetic mutations within a population of organisms over multiple generations. They achieve this by incorporating elements that suppress recombination between the mutated chromosome and its wild-type counterpart during meiosis. By preventing the exchange of genetic material between these chromosomes, balancer chromosomes ensure that the mutation of interest remains linked to other genetic markers carried on the balancer, thereby preventing its loss through genetic recombination.

In addition to their role in mutation maintenance, balancer chromosomes are instrumental in genetic mapping studies. These chromosomes serve as invaluable tools for mapping the location of unknown genes or genetic mutations in relation to other genetic markers. By exploiting the stable inheritance of balancer chromosomes and their associated markers, researchers can systematically dissect the genetic landscape of an organism and identify the precise genomic regions harboring genes of interest.

Furthermore, balancer chromosomes offer a unique opportunity to study the mechanisms of chromosome segregation during meiosis, the process by which genetic material is divided and distributed into gametes. By analyzing the behavior of balancer chromosomes during meiotic divisions, researchers can gain insights into the molecular mechanisms underlying chromosome segregation and the maintenance of genetic integrity.

Beyond their utility in laboratory research, balancer chromosomes also contribute to population genetics studies. These chromosomes enable researchers to investigate population dynamics, including the frequency and distribution of mutations within a population over time. By tracking the inheritance patterns of balancer chromosomes and associated mutations in large populations, researchers can uncover important insights into evolutionary processes, genetic drift, and the dynamics of allele frequencies within populations.

The balancer chromosomes represent powerful tools in genetic research, offering a versatile platform for maintaining mutations, mapping genes, studying chromosome segregation, and exploring population genetics dynamics. Their intricate design and multifaceted applications make them indispensable assets in the study of fundamental biological processes and the genetic basis of traits and diseases.

IV.8. The GAL4/UAS system

The GAL4/UAS system is a highly versatile and widely utilized genetic tool in *Drosophila* research, enabling precise spatial and temporal control of gene expression. At the core of this system is the GAL4 transcription factor, derived from yeast, which binds

specifically to the Upstream Activation Sequence (UAS) DNA motif. In the GAL4/UAS system, the GAL4 protein is expressed under the control of a tissue-specific or inducible promoter, directing its activity to specific cells or developmental stages of interest (Figure 26). Meanwhile, the target gene of interest is placed downstream of the UAS sequence. Upon GAL4 binding to the UAS sequence, transcription of the target gene is activated, allowing for its expression in the desired cell or developmental context. This system offers unparalleled flexibility, as GAL4 expression can be precisely manipulated using various promoters, while the target gene expression can be modulated by altering the number of UAS sequences or incorporating regulatory elements. Moreover, the GAL4/UAS system permits the spatial and temporal regulation of gene expression through the use of tissue-specific or inducible GAL4 drivers.




Figure 26: The GAL4/UAS system (Available via license: CC BY-NC-ND 4.0)

By leveraging the GAL4/UAS system, researchers can dissect complex biological processes, investigate gene function, and model human diseases with remarkable precision, making it an indispensable tool in Drosophila research.

IV.10. The FLP/FRT system

The FLP/FRT system is a sophisticated genetic tool widely employed in *Drosophila melanogaster* and other model organisms for precisely manipulating DNA sequences. At its core, this system relies on two key components: the Flippase (FLP) enzyme and the Flippase

Recognition Target (FRT) DNA sequences (Figure 27). The FLP enzyme catalyzes site-specific recombination between pairs of FRT sites, resulting in the excision, inversion, or translocation of DNA segments positioned between these sites.

The versatility of the FLP/FRT system lies in its ability to induce targeted genetic modifications with exceptional precision. Researchers can strategically introduce FRT sites into the genome at desired locations, either through transgenic insertion or by exploiting endogenous sequences with minimal disruption to the native genetic landscape. By controlling the expression of the FLP enzyme using tissue-specific or inducible promoters, researchers can precisely regulate the timing and spatial distribution of recombination events, allowing for the manipulation of gene expression or the creation of specific genetic alterations in particular cell types or developmental stages.




Figure 27: The FLP/FRT system (uploaded by [Ravi Munjaal](#)).

One of the key applications of the FLP/FRT system is in the generation of gene knockouts or knock-ins, where specific genes of interest are deleted, replaced, or modified. Additionally, this system enables the creation of chromosomal rearrangements, such as inversions or translocations, which can be used to study the effects of structural variations on gene expression and chromosome segregation. Furthermore, the FLP/FRT system facilitates lineage tracing studies by inducing heritable genetic markers or fluorescent reporters in specific cell lineages, aiding in the characterization of developmental processes and cell fate determination.

The FLP/FRT system offers unparalleled precision and versatility in genetic manipulation, making it an indispensable tool for elucidating gene function, studying developmental processes, and modeling human diseases in a wide range of biological systems. Its ability to induce targeted genetic modifications with high efficiency and accuracy has revolutionized genetic research and continues to drive advances in our understanding of fundamental biological processes.

IV.11. Limit of *Drosophila melanogaster* model

Complexity compared to mammals: While the fruit fly shares many genetic pathways and regulatory mechanisms with mammals, there are also significant differences in genetic organization and development between the two groups

Size and anatomy: The small size of the fruit fly limits the types of experiments that can be conducted.

Short lifespan: The relatively short lifespan of the fruit fly means that long-term studies, including those related to aging, may be limited.

Unique reproductive biology: Fruit fly reproduction and development occur differently compared to mammals.

Behavioral complexity: While fruit flies are used to study behavior, their behavioral complexity is much more limited compared to mammals, making it challenging to study certain aspects of animal behavior.

V. Mouse *Mus Musculus*

V.1. Description

The mouse, *Mus Musculus*, stands as a quintessential biological model organism, cherished for its remarkable genetic, physiological, and behavioral similarities to humans. Widely utilized across diverse fields of biomedical research, the mouse offers unparalleled advantages owing to its well-characterized genome, sophisticated genetic tools, and ease of manipulation. With a genome that shares approximately 85% similarity with humans, mice serve as invaluable models for studying gene function, disease mechanisms, and therapeutic interventions. Moreover, their relatively short generation time and large litter sizes facilitate rapid breeding and experimental throughput. Mice are amenable to genetic manipulation techniques such as gene targeting, transgenesis, and CRISPR/Cas9-mediated genome editing, allowing researchers to precisely engineer genetic modifications and study their effects on biological processes. Additionally, the availability of numerous inbred strains and genetically

modified lines enables the investigation of genetic diversity, gene-environment interactions, and complex traits. Beyond genetics, mice offer insights into various aspects of physiology, including metabolism, immunology, and neurobiology, making them indispensable tools for understanding human health and disease. Overall, the mouse model continues to play a central role in advancing our understanding of fundamental biological processes and in the development of novel therapeutics for human diseases.

V.2. Genetics advantages

The mouse, *Mus musculus*, offers several key genetic advantages that make it an invaluable model organism for biomedical research:

1. **Genetic Similarity to Humans:** The genetic makeup of mice shares a significant degree of similarity with humans, with approximately 85% of mouse genes having a counterpart in the human genome. This similarity allows researchers to study gene function, disease mechanisms, and therapeutic interventions in a system that closely resembles humans.
2. **Genetic Manipulation Techniques:** Mice are amenable to a wide range of genetic manipulation techniques, including gene targeting, transgenesis, and CRISPR/Cas9-mediated genome editing. These techniques enable precise modification of the mouse genome, facilitating the creation of genetically modified mouse models to study specific genes, pathways, and diseases.
3. **Inbred and Mutant Strains:** The availability of numerous inbred mouse strains and genetically modified lines allows researchers to study genetic diversity, gene-environment interactions, and complex traits. Inbred strains provide genetically homogeneous populations, while mutant strains with specific genetic alterations enable the study of gene function and disease phenotypes.
4. **Short Generation Time and Large Litter Sizes:** Mice have a relatively short generation time and large litter sizes, allowing for rapid breeding and experimental throughput. This facilitates the generation of large cohorts of animals for experimental studies, genetic crosses, and phenotype screening.
5. **Phenotypic Characterization:** Mice exhibit a wide range of phenotypic characteristics that can be easily assessed and quantified, including behavior, physiology, metabolism, and disease phenotypes. This enables researchers to study the effects of genetic

modifications on various aspects of biology and to model human diseases in a controlled laboratory setting.

The genetic advantages offered by the mouse make it an indispensable model organism for studying gene function, disease mechanisms, and therapeutic interventions in biomedical research.

V.3. Genetics description

The mouse, *Mus musculus*, reveals a complex yet highly organized genome structure. With 20 pairs of chromosomes, totaling 40 chromosomes in all, the mouse genome harbors approximately 20,000 to 25,000 genes. Among these genes, sex-linked genes are situated on the sex chromosomes, which dictate the sex determination of the organism. Male mice possess one X chromosome and one Y chromosome, while female mice carry two X chromosomes. The sequencing of the mouse genome in 2002 marked a significant milestone in genetic research, providing researchers with a comprehensive blueprint of the mouse genome and facilitating detailed investigations into gene function and regulation. Leveraging the genetic diversity and similarity to humans, mice serve as invaluable models for studying gene functions, regulatory mechanisms, and developmental processes. Additionally, mice are extensively used in biomedical research to investigate a broad spectrum of diseases, ranging from cancer and heart disease to diabetes and various other human conditions. Their genetic tractability, coupled with their physiological and behavioral resemblance to humans, renders mice indispensable tools for advancing our understanding of fundamental biological processes and human health.

V.4. Transgenic and Knockout Mouse Models in Disease Research

Mice stand as essential allies in unraveling the complexities of human diseases, primarily through the creation of transgenic or knockout mouse models (Figure 28). This intricate process commences with researchers pinpointing the gene of interest for investigation. Subsequently, they meticulously design an artificial DNA sequence engineered to disrupt the normal functioning of this gene. This artificial construct may involve the insertion of a mutated gene, the deletion of specific gene segments, or the introduction of regulatory elements to modulate gene expression. The designed DNA sequence is then introduced into mouse embryonic stem cells, a crucial step achieved through techniques like microinjection or electroporation. These genetically modified stem cells are carefully cultured and screened to identify those harboring the desired genetic modification.

Once identified, the modified stem cells are implanted into surrogate mouse embryos, where they contribute to the development of chimeric mice. These chimeras carry the genetic

modification in some of their cells, including the germ cells, enabling the transmission of the modified gene to subsequent generations. Through meticulous breeding strategies, researchers establish lines of transgenic or knockout mice carrying the desired genetic modification in all their cells.




Figure 28: The transgenic and Knockout Mouse Models (Available from [Cancers](#))

The generated knockout mice serve as invaluable tools for investigating the role of the target gene in disease pathogenesis. Phenotyping studies are conducted to comprehensively assess the effects of gene inactivation on various biological processes. This involves examining the knockout mice for alterations in development, morphology, physiology, behavior, and responses to specific conditions or stimuli. Sophisticated techniques such as high-resolution imaging, functional assays, and behavioral assessments are employed to dissect the intricate phenotypic changes resulting from gene knockout.

Furthermore, transgenic mouse models are instrumental in studying the consequences of gene overexpression or aberrant gene activity. By introducing exogenous genes or regulatory

elements into the mouse genome, researchers can explore the effects of gene dysregulation on disease initiation, progression, and therapeutic responses.

The utilization of transgenic and knockout mouse models provides researchers with invaluable insights into the molecular mechanisms underlying human diseases. These models serve as indispensable platforms for elucidating disease pathogenesis, identifying potential therapeutic targets, and evaluating novel treatment strategies with the ultimate goal of improving human health and well-being.

V.5. CRISPR-Cas9

A CRISPR-Cas9, a revolutionary genetic modification technique, has transformed mouse genetics by providing an efficient and precise method for editing the mouse genome. Adapted from bacterial immune systems, CRISPR-Cas9 utilizes the Cas9 enzyme and a guide RNA (gRNA) to target specific genomic loci in mice (Figure 30).




Figure 30: A CRISPR-Cas9 technique. Uploade by TAKARA.

Once guided to the target site, the Cas9 enzyme induces a double-strand break (DSB) in the mouse DNA. Subsequent repair of the DSB by the cell's natural DNA repair mechanisms, such as non-homologous end joining (NHEJ) or homology-directed repair (HDR), can lead to gene disruptions or precise genetic modifications, respectively. In NHEJ-mediated repair, small insertions or deletions (indels) may occur at the DSB site, resulting in gene knockout if frameshift mutations disrupt gene function. Conversely, HDR can be harnessed to introduce specific genetic alterations by providing a donor DNA template containing desired sequences.

This repair process enables researchers to create transgenic and knockout mouse models with unprecedented speed and accuracy, revolutionizing the study of gene function, disease mechanisms, and therapeutic strategies in the mouse model system.

V.6. A knock-in mouse model

A knock-in mouse model is a genetically engineered mouse in which a specific DNA sequence is inserted into the mouse genome at a precise location (Figure 31). Unlike knockout models, where a gene is disrupted or deleted, knock-in models introduce targeted genetic modifications, such as point mutations, reporter genes, or regulatory elements, into the mouse genome.




Figure 31: Knock-in mouse model. Uploaded by James Lee.

The creation of knock-in mouse models typically involves several steps. First, researchers design a targeting vector containing the desired DNA sequence to be inserted into the mouse genome, along with flanking regions that facilitate homologous recombination. This vector is then introduced into mouse embryonic stem cells (ESCs) via techniques such as electroporation or viral transduction.

The targeted ESCs are screened to identify those that have undergone successful homologous recombination, resulting in the insertion of the desired DNA sequence into the mouse genome. Positive ESC clones are then injected into mouse embryos to generate chimeric mice. These

chimeras contain a mixture of cells derived from both the host embryo and the genetically modified ESCs.

Chimeric mice are bred to produce offspring with the desired genetic modification in all cells of the body. The resulting knock-in mice carry the inserted DNA sequence at the specific genomic locus and can be used to study the function of the modified gene or regulatory element *in vivo*.

Knock-in mouse models have diverse applications in biomedical research. They are used to study the effects of specific genetic mutations on gene function, protein structure, and disease pathology. Additionally, knock-in models can be employed to generate reporter mice for visualizing gene expression patterns, lineage tracing, or monitoring cellular processes *in vivo*. Overall, knock-in mouse models provide valuable tools for understanding gene function, disease mechanisms, and therapeutic interventions in a controlled and genetically defined system.

V.7. Limit of Mouse *Mus Musculus*

While mouse models, particularly *Mus musculus*, are invaluable tools in biomedical research, they also come with several limitations that researchers must consider:

1. **Species Differences:** Despite genetic similarities, mice are not humans, and there can be differences in physiology, metabolism, and disease susceptibility between the two species. This can limit the translatability of findings from mouse studies to human biology.
2. **Complexity of Human Diseases:** Many human diseases are multifactorial and involve complex interactions between genetic, environmental, and lifestyle factors. Modeling such complexities in mice can be challenging and may not fully recapitulate the disease pathology seen in humans.
3. **Challenges in Modeling Certain Diseases:** Some diseases, such as neurodegenerative disorders or psychiatric conditions, are particularly challenging to model in mice due to differences in brain structure and function between mice and humans.
4. **Cost and Time of Studies:** Generating and maintaining mouse models can be expensive and time-consuming. This can limit the scale and scope of studies, especially for research groups with limited resources.

5. **Ethical and Animal Welfare Concerns:** The use of animals in research raises ethical considerations and animal welfare concerns. Researchers must adhere to strict regulations and guidelines to ensure the humane treatment of animals involved in experiments.
6. **Specificity of Mouse Strains:** Different mouse strains may exhibit variations in genetic background, immune response, and susceptibility to certain diseases. This can introduce variability and complicate data interpretation, particularly in studies involving multiple mouse strains.
7. **Environmental Influence:** Environmental factors, such as diet, housing conditions, and microbial exposure, can significantly impact experimental outcomes in mouse studies. Standardizing environmental conditions across experiments is challenging but crucial for reducing variability and ensuring reproducibility.
8. **Effects of Age:** Age-related changes can influence disease progression and treatment response in mouse models. Researchers must carefully consider the age of mice used in experiments to ensure relevance to the human condition, especially for age-related diseases.
9. **Potential for Contradictory Results:** Due to genetic and environmental variability, as well as differences in experimental protocols, findings from mouse studies may not always be consistent or reproducible. This highlights the importance of rigorous experimental design, replication, and validation in mouse research.

VI. Plants

VI.1. Description

Plants, as eukaryotic model organisms, offer unique advantages for studying various aspects of biology, including genetics, development, physiology, and environmental responses. These multicellular organisms belong to the Plantae kingdom and encompass a diverse range of species, from simple mosses to complex flowering plants.

One notable characteristic of plants is their eukaryotic cellular structure, characterized by membrane-bound organelles such as the nucleus, mitochondria, chloroplasts, and endoplasmic reticulum. This cellular organization allows for complex biological processes, including gene expression, protein synthesis, and metabolism.

Plants are also characterized by their multicellular body plans, which consist of various specialized tissues and organs, such as roots, stems, leaves, and flowers. This structural complexity enables plants to perform essential functions such as nutrient uptake, water transport, photosynthesis, reproduction, and response to environmental cues.

In terms of genetics, plants have a diploid genome organized into chromosomes, similar to other eukaryotic organisms. However, plants exhibit unique features such as alternation of generations, where they undergo both haploid (gametophyte) and diploid (sporophyte) phases during their life cycle (Figure 32). This phenomenon provides opportunities for studying genetic inheritance, meiosis, and reproductive biology.




Figure 32: Plants life cycle. <http://theseedsite.co.uk/lifecycle.html>. 16-06-2024.

Plants also possess a remarkable capacity for developmental plasticity, allowing them to adapt and respond to changing environmental conditions throughout their lifecycle. This plasticity is governed by intricate regulatory networks involving hormones, transcription factors, and epigenetic modifications.

Furthermore, plants exhibit diverse physiological responses to environmental stimuli, including light, temperature, water availability, and nutrient levels. These responses are mediated by signaling pathways, ion transport mechanisms, and metabolic adjustments that enable plants to thrive in a wide range of habitats.

Given their biological complexity and amenability to genetic manipulation, plants serve as valuable model organisms for addressing fundamental questions in biology and for applied research in agriculture, biotechnology, and environmental science. Plant model systems such as *Arabidopsis thaliana*, maize (*Zea mays*), and rice (*Oryza sativa*) have been extensively

studied and have provided insights into fundamental biological processes that are relevant across the eukaryotic kingdom.

VI.2. Genetics advantages

One significant genetic advantage of plants as model organisms lies in their relatively simple and well-characterized genomes. Many plant species have compact genomes with fewer genes compared to animals, making them more amenable to genetic analysis and manipulation. For instance, the model plant *Arabidopsis thaliana* has a relatively small genome size of around 125 million base pairs, encoding approximately 27,000 genes. This simplicity facilitates the identification and functional characterization of genes involved in various biological processes.

Additionally, the high degree of conservation of gene function across plant species allows researchers to extrapolate findings from one species to another, enabling comparative genomics and evolutionary studies. This conservation extends not only to protein-coding genes but also to regulatory elements, signaling pathways, and metabolic networks.

Moreover, the availability of extensive genomic resources, such as fully sequenced genomes, genetic maps, and mutant collections, further enhances the utility of plants as genetic model organisms. These resources enable researchers to conduct genome-wide studies, identify gene function, and investigate gene-environment interactions with unprecedented precision and efficiency.

The genetic simplicity, conservation, and resources available in plant model systems provide researchers with powerful tools for unraveling the genetic basis of fundamental biological processes and for addressing key questions in genetics, genomics, and evolutionary biology.

VI.3. Genetics description

In plant genetics, the chromosome number and genome organization play fundamental roles in shaping the genetic landscape and determining various traits and characteristics of plant species. The chromosome number refers to the total number of chromosomes present in the nucleus of a plant cell, which typically varies among different plant species. This number is often denoted as $2n$, where n represents the haploid number of chromosomes. For example, in diploid organisms, such as most higher plants, the chromosome number is usually denoted as $2n$, indicating that each cell contains two sets of chromosomes, one inherited from each parent.

The genome of a plant encompasses all the genetic material, including DNA sequences and associated proteins, contained within the chromosomes. The plant genome consists of nuclear DNA located within the nucleus, as well as DNA in organelles such as chloroplasts and

mitochondria. The nuclear genome is organized into chromosomes, with each chromosome containing multiple genes arranged along its length. Genes are segments of DNA that encode instructions for the synthesis of proteins, which are essential molecules involved in various cellular processes, including growth, development, metabolism, and response to environmental stimuli.

The organization of genes within the plant genome can vary widely among species, with some genomes containing large numbers of genes distributed across multiple chromosomes, while others have smaller, more compact genomes with fewer genes. The size and complexity of the plant genome are influenced by factors such as genome duplication events, gene duplication and loss, and the presence of repetitive DNA sequences.

Genetic studies in plants often involve the analysis of specific genes or gene families responsible for important traits, such as disease resistance, yield, and nutritional quality. Researchers use a variety of molecular biology techniques, including DNA sequencing, genetic mapping, and functional genomics approaches, to identify, characterize, and manipulate genes of interest. Understanding the relationship between chromosome number, genome organization, and gene function is essential for unraveling the genetic basis of plant traits and for developing strategies to improve crop performance, enhance agricultural productivity, and address global challenges in food security and sustainability.

VI.4. Rice (*Oryza sativa*): A Model for Monocots

Rice (*Oryza sativa*) stands out as a model organism for monocots, offering invaluable insights into plant genetics and serving as a cornerstone in global agriculture. Its significance lies not only in its role as one of the world's primary food sources but also in its potential to inform agricultural practices and enhance crop productivity. With its relatively small genome size and extensive genomic resources, rice serves as a model system for understanding the genetic basis of important agronomic traits, such as yield, disease resistance, and tolerance to environmental stresses.

The compact genome of rice, comprising 24 chromosomes (12 pairs), has been fully sequenced for both the japonica and indica subspecies. This feat has paved the way for comprehensive genetic analyses and facilitated the mapping of numerous genes associated with key agricultural traits. The Rice Genome Annotation Project (RGAP) and the Rice Annotation Project Database (RAP-DB) provide comprehensive annotations and genomic information for japonica and indica rice, enabling researchers to dissect the genetic mechanisms underlying rice phenotypes.

Through the concerted efforts of the scientific community, rice research has yielded significant advancements in variety selection and crop improvement. The availability of genomic data and comparative databases, such as Gramene, has facilitated the identification of candidate genes for targeted breeding programs and the development of genetically improved rice varieties tailored to specific environmental conditions and agricultural requirements.

The Rice serves as an invaluable model for monocots, offering a platform for elucidating fundamental principles of plant genetics and driving innovations in agriculture. Its compact genome, coupled with extensive genomic resources, makes rice an indispensable tool for addressing global challenges in food security, sustainability, and resilience to environmental change. By harnessing the genetic potential of rice, researchers can continue to unlock new avenues for enhancing crop productivity and ensuring the well-being of future generations.

VI.5. *Physcomitrella patens*: A Model for Bryophytes

Physcomitrella patens, often regarded as one of the most primitive terrestrial plants, holds a pivotal position in the evolutionary trajectory of land plants. Its small size, rapid life cycle, and amenability to genetic manipulation have established it as an ideal model organism for unraveling the intricacies of fundamental plant biology. This moss species offers invaluable insights into key processes such as vegetative organ development, reproductive strategies, and mechanisms underlying environmental stress tolerance. With 27 chromosomes and a genome size of 480 Mb, *Physcomitrella patens* serves as a genomic treasure trove for researchers seeking to decipher the genetic basis of plant evolution and adaptation. Databases like Cosmoss.org and Phytozome provide comprehensive resources for exploring the moss genome, offering genomic sequences, gene expression data, and valuable insights into gene function and evolution across plant species. Through continued investigation and utilization of this model organism, scientists can uncover new dimensions of plant biology and contribute to our understanding of the fundamental principles governing life on land.

VI.6. Molecular genetics tools used in the study of model plants

In the study of model plants, molecular genetics tools play a crucial role in elucidating the genetic mechanisms underlying various biological processes. These tools enable researchers to investigate gene function, regulation, and expression, providing insights into fundamental aspects of plant biology. Techniques such as polymerase chain reaction (PCR), DNA sequencing, and genome editing technologies like CRISPR-Cas9 allow for the precise manipulation and analysis of plant genomes. Transcriptomics approaches, such as RNA sequencing (RNA-seq) and microarray analysis, facilitate the study of gene expression patterns

and regulatory networks in response to developmental cues or environmental stimuli. Additionally, genetic mapping techniques, including linkage analysis and quantitative trait locus (QTL) mapping, help identify genomic regions associated with specific traits or phenotypes of interest. Moreover, molecular markers such as single nucleotide polymorphisms (SNPs) and simple sequence repeats (SSRs) are invaluable tools for genetic diversity analysis, population genetics, and marker-assisted breeding programs in plants. By leveraging these molecular genetics tools, researchers can uncover novel insights into plant biology, accelerate crop improvement efforts, and address pressing challenges in agriculture and environmental sustainability.

VI.7. Limits of plants model

The limitation of plant models is the complexity of translating findings from model species to agriculturally important crops. While plant models such as *Arabidopsis thaliana* provide valuable insights into fundamental biological processes, they may not fully represent the genetic diversity and physiological traits found in crop plants. As a result, discoveries made in model species may not always directly translate to improvements in crop yield, disease resistance, or stress tolerance. Additionally, the genomic and physiological differences between model plants and crops may present challenges when attempting to apply findings from model systems to practical agricultural settings. Therefore, researchers must carefully consider the relevance and applicability of findings from plant models to crop species and may need to conduct additional studies in crop plants to validate and implement research findings effectively.

Chapter II: Molecular Basis of Human Genetic Diseases

I. Positional cloning

Positional cloning, also known as map-based cloning, is a molecular genetics technique used to identify and isolate genes responsible for specific traits or phenotypes of interest in plant models. The process involves systematically mapping the genomic region containing the gene of interest followed by the isolation and characterization of the gene itself.




Figure 33: Positional cloning. (Dalmais *et al.*, 2008).

The first step in positional cloning is to generate mapping populations, typically through crosses between individuals with contrasting phenotypes. These populations allow researchers to identify genetic markers, such as molecular markers like single nucleotide polymorphisms (SNPs) or simple sequence repeats (SSRs), that are linked to the trait of interest. By genotyping the mapping populations, researchers can construct a genetic linkage map that indicates the relative positions of markers along the chromosomes.

Once the genomic region containing the gene of interest is narrowed down through linkage analysis, candidate genes within this region are identified based on their predicted function, expression patterns, or similarity to genes with known functions in other species. These candidate genes are then sequenced and analyzed to identify mutations or polymorphisms associated with the phenotypic trait.

Finally, functional validation experiments are conducted to confirm the role of the identified gene in determining the observed phenotype. This may involve techniques such as transgenic complementation assays, where the candidate gene is introduced into plants lacking the gene, or gene knockout/knockdown studies, where the gene is selectively disrupted to assess its effects on the phenotype.

Positional cloning has been instrumental in identifying genes underlying various traits in plant models, including disease resistance, stress tolerance, and developmental processes. By uncovering the genetic basis of these traits, positional cloning facilitates the development of improved crop varieties through targeted breeding and genetic engineering approaches, ultimately contributing to agricultural sustainability and food security.

II. Chromosomal abnormality

II.1. Background

The chromosomal formula always starts with the total number of chromosomes (including sex chromosomes), followed by a comma, then, without space, the enumeration of the sex chromosomes. Thus, the normal karyotype is designated as follows: 46,XX female karyotype without detected abnormalities 46,XY male karyotype without detected abnormalities In onco-hematology, the number of mitoses studied must be indicated in brackets, without space after the chromosomal formula: 46,XX[15] female karyotype without detected abnormalities in the 15 mitoses studied For the description of rearrangements, the anomalies of the sex chromosomes are always presented first, followed by the anomalies of the autosomes, which are listed in ascending order of their numbers, regardless of the type of aberration. For each chromosome, numerical anomalies are presented before structural anomalies. The chromosomal formula is written in one go, without space, punctuated by commas.

II.2. Identification and definition of landmarks, regions, and bands

Each chromosome is considered as consisting of a continuous series of bands without interbands. By definition, a band is a segment of chromosome precisely differentiable from adjacent segments by its lighter or darker staining after applying staining techniques. A landmark is a permanent and distinct morphological trait that is significantly helpful in the identification of the chromosome. The landmarks are: the centromeres, the telomeres, and certain characteristic bands. A region is a segment of chromosome located between two consecutive landmarks. By definition, a band used as a landmark belongs to the most distal region and is the first band of that region. Bands and regions are numbered from the centromere towards the telomere. Bands can be subdivided into sub-bands, which can be further subdivided into sub-sub-bands. To designate a band on a chromosome, you must write the chromosome number, the symbol of the arm (p or q), the number of the region, the number of the band in that region, and if necessary, the number of the sub-band and that of the sub-sub-band. In this case, the number of the band and that of the sub-band are separated by a dot (Figure 34).




Figure 34: Identification of landmarks, regions, and bands of chromosome. Chromosomal anomalies can be broadly categorized into numerical and structural anomalies. Upload by Frontières.

II.3. Numerical Anomalies

Numerical anomalies involve an abnormal number of chromosomes and can be further divided into aneuploidy and polyploidy (Figure 35).

A. Aneuploidy Aneuploidy refers to the presence of an abnormal number of chromosomes, which can be either more or fewer than the normal diploid number.




Figure 35: Nondisjunction Diagrams. (<https://quizlet.com/246766210/chapter-12-section-4-meiotic-nondisjunction-diagram/>. 06-06-2024)

Monosomy: This is a type of aneuploidy where there is one chromosome missing from a pair ($2n-1$). For example, Turner syndrome is characterized by monosomy X ($45,X$), where there is only one X chromosome instead of two sex chromosomes.

- **Trisomy:** This is a type of aneuploidy where there is an extra chromosome, resulting in three copies of a particular chromosome ($2n+1$). Examples include:
 - Trisomy 21 (Down syndrome)
 - Trisomy 18 (Edwards syndrome)
 - Trisomy 13 (Patau syndrome)

B. Polyploidy Polyploidy refers to having more than two complete sets of chromosomes. This is less common in humans but is often seen in plants (Figure 36).

- **Triploidy:** Three sets of chromosomes ($3n$)
- **Tetraploidy:** Four sets of chromosomes ($4n$)




Figure 36: Representation of polyploidies. Upload by nature review.

II.4. Structural Anomalies

Structural anomalies involve changes in the structure of chromosomes and include various types of rearrangements.

A. Types of Structural Anomalies

- **Deletions:** A part of the chromosome is missing or deleted. This can lead to a loss of genetic material and potentially severe genetic disorders.

- **Duplications:** A part of the chromosome is duplicated, resulting in extra genetic material.
- **Inversions:** A segment of the chromosome breaks off, flips around, and reattaches, thus reversing the order of the genes. This can be pericentric (including the centromere) or paracentric (not including the centromere).
- **Translocations:** A segment of one chromosome is transferred to another chromosome. There are different types of translocations :
 - **Reciprocal Translocation:** Involves an exchange of segments between two non-homologous chromosomes. This can lead to a balanced translocation, where no genetic material is gained or lost, or an unbalanced translocation, where there is a gain or loss of genetic material (Figure 37).




Figure 37: Reciprocal translocation. Upload by Brain Brooder.

- **Robertsonian Translocation:** A specific type of translocation involving the fusion of two acrocentric chromosomes (chromosomes with very short arms), resulting in the loss of the short arms and fusion of the long arms. This is common in chromosomes 13, 14, 15, 21, and 22 and can lead to conditions like Down syndrome when chromosome 21 is involved (Figure 38).




Figure 38: Robertsonian Translocation. Upload by HUMAN Embryology, embryogenesis

- **Insertions:** A segment of one chromosome is inserted into another chromosome. This can disrupt the genetic sequence and lead to genetic disorders.
- **Rings:** A chromosome forms a ring shape due to deletions in telomeres, causing the ends to fuse together (Figure 39).




Figure 39: Chromosome ring. By database center for life sciences.

III. Position-Independent Disease Gene Identification Strategies

Position-independent disease gene identification strategies are methods used to identify genes responsible for diseases without prior knowledge of their chromosomal locations. These approaches leverage various genomic technologies and data to pinpoint disease-associated

genes based on their function, expression, or other characteristics. Here are some common strategies:

➤ **Functional Cloning:** This involves identifying a gene based on its known function rather than its location. Researchers screen for gene products (proteins or RNA) with a particular function and then identify the corresponding gene.

➤ **Candidate Gene Approach:** Researchers select genes that are likely to be involved in the disease based on their known or suspected function in biological pathways relevant to the disease. These genes are then tested for mutations in affected individuals.

➤ **Comparative Genomics:** By comparing the genomes of different species, researchers can identify conserved genes that are likely to be essential and may be implicated in disease when mutated.

➤ **Gene Expression Profiling:** This involves comparing the gene expression patterns between diseased and healthy tissues to identify genes that are differentially expressed and may play a role in the disease.

Proteomics: Similar to gene expression profiling, but at the protein level. Researchers identify proteins that are differentially expressed or modified in disease states.

III.1. Diagnosis Using Genetic Markers

Diagnosis using genetic markers is a powerful approach in identifying and understanding genetic disorders. This approach can be categorized into three types: direct, indirect, and semi-direct diagnosis.

a. Direct Diagnosis

Direct diagnosis involves detecting specific mutations within a gene that are known to cause a disease. This approach is highly accurate and can directly confirm the presence of a genetic disorder. Techniques used include:

- **PCR (Polymerase Chain Reaction):** This technique amplifies specific DNA segments to detect known mutations. It's a quick and efficient method to screen for genetic alterations. For example, in sickle cell anemia, PCR can be used to amplify and then identify the sickle cell mutation in the HBB gene.
- **Sequencing:** Sequencing identifies the exact sequence of nucleotides in a gene, revealing the presence of mutations. Methods such as Sanger sequencing or next-generation sequencing (NGS) are commonly used. For instance, sequencing can detect

a wide range of mutations in the BRCA1 and BRCA2 genes, which are associated with increased risk of breast and ovarian cancer.

- **Real-time PCR (qPCR):** This technique quantifies DNA in real time and can detect specific mutations. It is highly sensitive and can measure the amount of mutated DNA. For example, qPCR can be used to quantify the BCR-ABL fusion gene in chronic myeloid leukemia.

Example: Direct diagnosis of cystic fibrosis involves identifying mutations in the CFTR gene. The most common mutation, $\Delta F508$, can be detected using PCR followed by restriction enzyme digestion or sequencing.

b. Indirect Diagnosis

Indirect diagnosis relies on linkage analysis using genetic markers that are co-inherited with the disease gene. This method is particularly useful when the exact gene causing the disease is unknown, but its chromosomal location is known.

- **Linkage Analysis:** This method involves studying families with a history of the disease to identify genetic markers that segregate with the disease phenotype. By analyzing recombination events in families, researchers can map the location of the disease gene relative to known markers.
- **Haplotype Mapping:** This approach uses groups of markers (haplotypes) to track the inheritance of the disease gene within families. Haplotypes are combinations of alleles at adjacent loci that are transmitted together. This method helps narrow down the region of the chromosome that is associated with the disease.

Example: Using markers linked to the BRCA1 gene to infer the risk of breast cancer in family members. By analyzing markers closely linked to BRCA1, genetic counselors can identify individuals at high risk.

c. Semi-Direct Diagnosis

Semi-direct diagnosis combines elements of both direct and indirect methods. It involves identifying genetic markers close to or within a candidate gene that is suspected of causing the disease. This approach is useful when there is strong evidence implicating a specific region of the genome, but the exact mutation is not yet known.

- **Association Studies:** These studies identify markers that are statistically associated with the disease in a population. They often involve genome-wide association studies (GWAS) that scan the entire genome to find genetic variations associated with a particular disease. GWAS can identify single nucleotide polymorphisms (SNPs) that are more frequent in individuals with the disease.
- **Fine Mapping:** Once a region associated with the disease is identified, fine mapping is used to pinpoint the exact gene or mutation within the linked region. This involves a detailed analysis of the candidate region to identify the causative genetic variation.

Example: Identifying susceptibility loci for complex diseases like diabetes through GWAS. After locating a region associated with diabetes, fine mapping can help identify the specific gene or mutation responsible for the increased risk.

IV. Testing a Candidate Gene Defined by Positional Cloning

Positional cloning is a method used to identify the location of disease-causing genes on a chromosome. Once a candidate gene is identified through positional cloning, various methods are used to test and confirm that this gene is indeed responsible for the disease. This process involves several steps:

IV.1. Gene Identification and Sequencing

Isolation and Sequencing: The candidate gene identified through positional cloning is isolated, and its entire sequence is determined. This involves sequencing the gene to identify its exons, introns, promoter regions, and regulatory elements.

IV.2. Mutation Analysis

Screening for Mutations: The candidate gene is screened for mutations in individuals affected by the disease. Common techniques include PCR amplification of gene regions followed by sequencing or mutation scanning methods such as denaturing high-performance liquid chromatography (DHPLC).

Comparative Analysis: The sequences obtained from affected individuals are compared with those from unaffected individuals to identify disease-specific mutations. This can involve looking for single nucleotide polymorphisms (SNPs), insertions, deletions, or more complex rearrangements.

IV.3. Functional Studies

Expression Analysis: Assessing the expression of the candidate gene in tissues relevant to the disease can provide evidence of its role. Techniques such as quantitative PCR (qPCR), Northern blotting, or RNA sequencing (RNA-seq) are used to measure gene expression levels.

Protein Studies: Investigating the protein product of the candidate gene can involve Western blotting, immunohistochemistry, or mass spectrometry to confirm the presence, abundance, and localization of the protein in disease-relevant tissues.

Functional Assays: These assays test the function of the mutated gene product. For example, enzyme activity assays, cellular localization studies, and interaction assays can help determine how mutations affect the gene's function.

IV.4. Genetic Linkage and Association Studies

Linkage Analysis: Further linkage studies in additional families can help confirm that the candidate gene is consistently linked to the disease phenotype.

Association Studies: Population-based studies can be used to assess whether mutations in the candidate gene are statistically associated with the disease in a larger population.

IV.5. Animal Models

Knockout Models: Creating animal models (such as mice) with the candidate gene knocked out (disabled) can help determine the gene's function and its role in the disease.

Transgenic Models: Introducing the human candidate gene with the identified mutation into an animal model can provide insights into how the mutation affects gene function and contributes to the disease phenotype.

IV.6. Rescue Experiments

Gene Rescue: Introducing a normal copy of the candidate gene into a model organism or cell line with the mutated gene can help confirm its role in the disease. If the normal gene rescues the disease phenotype, it provides strong evidence that the candidate gene is responsible.

IV.7. Pathway Analysis:

Understanding the pathways in which the candidate gene operates can provide further evidence of its role in the disease. This involves studying the interactions between the candidate gene and other genes and proteins in relevant biological pathways.

V. Identifying Causative Variants from Association Studies

Identifying causative variants from association studies is a critical step in understanding the genetic basis of complex diseases. This process begins with genome-wide association studies (GWAS), which involve scanning the genomes of large cohorts to find single nucleotide polymorphisms (SNPs) and other genetic variations that are significantly associated with a disease or trait. Once GWAS identifies regions of the genome linked to the disease, the next step is fine mapping, which narrows down these regions to pinpoint the most likely causative variants. Fine mapping uses high-density genotyping and imputation methods to identify a smaller set of candidate variants within the associated regions.

To determine which of these candidate variants are truly causative, researchers perform functional annotation. This step involves using bioinformatics tools to predict the impact of the variants on gene function, such as changes in protein coding, splicing, regulatory element disruption, or gene expression. Databases like ENCODE and Roadmap Epigenomics provide information about regulatory elements and chromatin states that help predict the functional consequences of the variants.

Integration of multi-omics data is crucial for identifying causative variants. This includes expression quantitative trait loci (eQTL) analyses, which link variants to gene expression changes, and chromatin immunoprecipitation sequencing (ChIP-seq) data, which identifies protein-DNA interactions. By correlating genetic variants with changes in gene expression or chromatin accessibility, researchers can infer potential mechanisms by which the variants influence disease.

Experimental validation is the next crucial step. This involves *in vitro* assays, such as reporter gene assays to test the impact of regulatory variants on gene expression, and CRISPR/Cas9 genome editing to directly assess the effect of specific variants in cellular models. *In vivo* studies, using model organisms like mice or zebrafish, can also provide functional evidence for the role of candidate variants in disease phenotypes.

Additionally, pathway and network analyses can help contextualize the identified variants within biological pathways, revealing how genetic perturbations might lead to disease. This involves examining whether the genes affected by the variants are part of known disease-relevant pathways or interact with other proteins implicated in the disease.

By combining these approaches GWAS, fine mapping, functional annotation, integration of multi-omics data, experimental validation, and pathway analysis—researchers can robustly identify and confirm causative variants. This comprehensive strategy not only helps in understanding the genetic architecture of diseases but also paves the way for developing targeted therapies and personalized medicine approaches.

VI. Eight Examples of Disease Gene Identification

VI.1. The Duchenne muscular dystrophy (DMD)

VI.1.1. Description

Duchenne muscular dystrophy (DMD) is a severe form of muscular dystrophy that predominantly affects boys, with an incidence of approximately 1 in 3,500 live male births worldwide. The disease is characterized by progressive muscle weakness and degeneration, starting typically between the ages of 2 and 5. Early symptoms include delays in motor milestones such as sitting, standing, and walking. As the disease progresses, children experience difficulty climbing stairs, frequent falls, and a characteristic waddling gait. By the age of 12, most patients lose the ability to walk and become wheelchair-dependent (Figure 40).




Figure 40: muscular dystrophy. Upload Muscular Dystrophy Association (MDA).

DMD also affects cardiac and respiratory muscles, leading to cardiomyopathy and respiratory failure, which are major causes of morbidity and mortality. The average life expectancy for individuals with DMD is in the late 20s to early 30s, though advancements in medical care are gradually improving outcomes.

VI.1.2. Genetic Description

Duchenne muscular dystrophy is caused by mutations in the DMD gene, located on the X chromosome at position Xp21.2. This gene spans over 2.2 million base pairs and contains 79 exons, making it one of the largest human genes (Figure 41).




Figure 41: DMD gene organization. (<https://www.mdpi.com/2073-4425/13/7/1241>.
06-06-2024)

The DMD gene encodes the protein dystrophin, which is crucial for maintaining the structural integrity of muscle cell membranes. Two important genetic markers for DMD include:

1. **Exon Deletions:** Large deletions of one or more exons in the DMD gene account for approximately 60-70% of all DMD cases (Figure 42). These deletions often disrupt the reading frame of the gene, leading to a truncated, non-functional dystrophin protein. Commonly deleted exons include 45-55, which is a mutation hotspot.
2. **Point Mutations:** These include single nucleotide changes, small insertions, or deletions that result in nonsense mutations, missense mutations, or splicing defects. Point mutations account for about 20-30% of DMD cases. Nonsense mutations

introduce a premature stop codon, leading to truncated dystrophin, while missense mutations alter the amino acid sequence, potentially affecting protein function.




Figure 42: Genetic distribution of DMD. <https://totalcommunitycare.co.uk/duchenne-muscular-dystrophy/>. 06-06-2024.

VI.1.3. Technique Used for Diagnosis

Several advanced genetic techniques are employed to diagnose DMD:

1. **Multiplex Ligation-dependent Probe Amplification (MLPA):** MLPA is a technique used to detect deletions and duplications of one or more exons in the DMD gene. It involves the hybridization of probes to target sequences, followed by ligation and amplification. This method is highly sensitive and can identify the specific exons that are deleted or duplicated, providing detailed information about the mutation.

2. **Next-Generation Sequencing (NGS):** NGS is a comprehensive method that sequences the entire DMD gene at high resolution. This technique is capable of detecting small mutations, including point mutations, small insertions, and deletions that MLPA might miss. NGS provides a complete genetic profile of the DMD gene, facilitating the identification of any pathogenic variants.

3. **Sanger Sequencing:** For confirming point mutations identified by NGS, Sanger sequencing can be used. This method involves sequencing a specific region of the DMD gene to validate the presence of a mutation. Although labor-intensive, it is considered the gold standard for mutation verification.

4. **Quantitative PCR (qPCR):** This technique can be used for the quantitative analysis of gene copy numbers and is sometimes employed as an adjunct to MLPA to confirm deletions or duplications.

VI.2. Cystic fibrosis

VI.2.1. Description

Cystic fibrosis (CF) is a life-threatening genetic disorder that primarily affects the respiratory and digestive systems. It is characterized by the production of thick, sticky mucus that clogs the airways and leads to severe respiratory and gastrointestinal complications. Symptoms of CF include chronic coughing, frequent lung infections, sinus infections, poor growth, and difficulty absorbing nutrients due to pancreatic insufficiency. The disease is caused by mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene (Figure 43), which encodes a protein involved in the transport of chloride and sodium ions across cell membranes. This dysfunction leads to the buildup of mucus in various organs, particularly the lungs and pancreas. CF is most common in individuals of Northern European descent, with an incidence of about 1 in 2,500 to 3,500 live births.




Figure 43: Cystic fibrosis RNF5 expression. by [University of California - San Diego](https://www.ucsd.edu/)

VI.2.2. Genetic Description

Cystic fibrosis is an autosomal recessive disorder, meaning that a person must inherit two defective CFTR genes (one from each parent) to develop the disease (Figure 44). Two common genetic markers for CF include:

1. **Δ F508 Mutation:** The most prevalent CFTR mutation, found in approximately 70% of CF patients worldwide. It involves the deletion of three nucleotides leading to the loss of phenylalanine at position 508 of the CFTR protein. This mutation causes misfolding and degradation of the protein, preventing it from reaching the cell membrane.
2. **G542X Mutation:** This is a nonsense mutation that results in a premature stop codon at position 542. It is one of the many mutations that result in the production of a truncated, non-functional CFTR protein. This type of mutation prevents the proper formation and function of the CFTR protein, contributing to the clinical manifestations of CF.




Figure 44: Mutations at CFTR gene. Available from Disease Markers.

VI.2.3. Technique Used for Diagnosis

Several genetic techniques are used for diagnosing CF:

1. **Sweat Chloride Test:** While not a genetic test, it measures the concentration of chloride in sweat and is the gold standard for diagnosing CF. Elevated chloride levels are indicative of CF.
2. **DNA Sequencing:** Comprehensive sequencing of the CFTR gene is performed to identify mutations. Next-Generation Sequencing (NGS) is particularly useful for detecting a wide range of mutations, including small deletions, insertions, and single nucleotide changes across the entire gene.
3. **Allele-Specific Oligonucleotide (ASO) Hybridization:** This technique involves using probes specific to common CFTR mutations, such as $\Delta F508$ and G542X, to identify these mutations in DNA samples. It is a rapid and targeted approach for screening known mutations.
4. **Multiplex Ligation-dependent Probe Amplification (MLPA):** MLPA can detect larger deletions and duplications in the CFTR gene, which may not be identified by standard sequencing methods. It is useful for comprehensive analysis of structural variations within the gene.
5. **Panel Testing:** Commercially available CF mutation panels test for a predefined set of common CFTR mutations. These panels are useful for initial screening, especially in populations with well-characterized mutation frequencies.

VI.3. Branchio-Oto-Renal Syndrome

VI.3.1. Description

Branchio-Oto-Renal (BOR) syndrome is a genetic disorder characterized by abnormalities affecting the branchial arches, ears, and kidneys (Figure 45). The condition manifests with a wide range of clinical features, including branchial cleft cysts or fistulas, hearing loss, and kidney malformations that can lead to chronic renal failure. Hearing loss associated with BOR syndrome can be conductive, sensorineural, or mixed and can vary in severity. The syndrome may also present with preauricular pits, ear tags, and structural ear anomalies. The severity and combination of symptoms can vary greatly among affected individuals, even within the same family. BOR syndrome is caused by mutations in specific genes that are crucial for the development of these structures during embryogenesis.

encodes a transcription factor involved in the development of various organs, including the ears and kidneys. Mutations in SIX1 are often missense mutations that alter the DNA-binding or protein interaction capabilities of the SIX1 protein, leading to developmental anomalies.

VI.3. Technique Used for Diagnosis

Several genetic techniques are employed to diagnose BOR syndrome:

1. **Sanger Sequencing:** This method is used to sequence specific exons of the EYA1 and SIX1 genes to identify point mutations, small insertions, and deletions. It provides high accuracy for detecting known and novel mutations in these genes.
2. **Multiplex Ligation-dependent Probe Amplification (MLPA):** MLPA is used to detect larger deletions or duplications within the EYA1 gene. This technique involves the hybridization of probes to target sequences, followed by ligation and amplification, allowing for the identification of copy number variations that might be missed by sequencing alone.
3. **Next-Generation Sequencing (NGS):** NGS is employed for comprehensive analysis of the EYA1 and SIX1 genes and can include whole exome or targeted gene panel sequencing. This technique allows for the detection of a broad spectrum of mutations, including those that are rare or previously uncharacterized.
4. **Array Comparative Genomic Hybridization (aCGH):** aCGH can be used to identify larger genomic deletions or duplications encompassing the EYA1 or SIX1 loci. This technique compares the patient's DNA to a reference genome to detect variations in DNA copy number.

VI.4. Multiple sulfatase deficiency

VI.4.1. Description

Multiple sulfatase deficiency (MSD) (Figure 47) is a rare, inherited lysosomal storage disorder that affects multiple sulfatase enzymes, leading to the accumulation of sulfated substrates in various tissues. This accumulation causes progressive and widespread organ dysfunction. Symptoms of MSD typically appear in infancy or early childhood and include developmental delay, coarse facial features, hepatosplenomegaly, skeletal abnormalities, ichthyosis (thick, scaly skin), neurological decline, and other systemic issues. MSD is often fatal in childhood due to the progressive nature of the disease and the severe impact on multiple organ systems.

VI.4.3. Technique Used for Diagnosis

Several advanced genetic techniques are used to diagnose MSD:

1. **Enzyme Activity Assays:** Initial diagnosis often involves measuring the activity of multiple sulfatase enzymes (such as arylsulfatase A, B, and C) in leukocytes or fibroblasts. Reduced activity of these enzymes suggests MSD and warrants further genetic testing.
2. **Sanger Sequencing:** This technique is used to sequence the SUMF1 gene to identify point mutations, small insertions, and deletions. Sanger sequencing provides high accuracy and is often used to confirm the diagnosis of MSD by detecting known pathogenic variants in the SUMF1 gene.
3. **Next-Generation Sequencing (NGS):** NGS allows for comprehensive analysis of the SUMF1 gene, enabling the detection of a wide range of mutations, including novel or rare variants that may not be covered by Sanger sequencing alone. NGS can include whole exome sequencing or targeted gene panels specific to lysosomal storage disorders.
4. **Multiplex Ligation-dependent Probe Amplification (MLPA):** MLPA can be used to detect larger deletions or duplications within the SUMF1 gene that may not be identified by sequencing methods. This technique involves the hybridization of probes to target sequences, followed by ligation and amplification to identify copy number variations.
5. **Genetic Panel Testing:** Commercially available genetic panels for lysosomal storage disorders can include the SUMF1 gene among others, providing a broad screening tool for various related conditions. These panels are useful for differential diagnosis when the clinical presentation is unclear or overlapping with other lysosomal storage disorders.

VI.5. Intestinal lactase persistence

VI.5.1. Description

Intestinal lactase persistence is a genetic trait in which lactase, the enzyme responsible for digesting lactose (the sugar found in milk and dairy products) (Figure 49), continues to be produced into adulthood. This trait allows individuals to digest lactose without experiencing symptoms such as bloating, diarrhea, and abdominal pain, which are characteristic of lactose intolerance. Lactase persistence is most common among populations with a long history of dairy consumption, such as those in Northern Europe, certain African tribes, and some Middle

Eastern groups. The prevalence of lactase persistence varies widely across different ethnic groups and is less common in East Asian, Native American, and some African populations.




Figure 49: Lactase Catalysis. Available via license: [CC BY 3.0](https://creativecommons.org/licenses/by/3.0/).

VI.5.2. Genetic Description

Lactase persistence is associated with specific genetic variants located upstream of the LCT gene, which encodes the lactase enzyme. These variants act as regulatory elements that maintain the expression of the LCT gene into adulthood. Two key genetic markers associated with lactase persistence include:

1. **-13910C>T Polymorphism (rs4988235):** This single nucleotide polymorphism (SNP) is located approximately 13.9 kb upstream of the LCT gene, within the MCM6 gene (Figure 50). The T allele of this SNP is strongly associated with lactase persistence, especially in European populations. Individuals with the C allele typically exhibit lactase non-persistence (lactose intolerance).
2. **-22018G>A Polymorphism (rs182549):** Another SNP located upstream of the LCT gene, also within the MCM6 gene. The A allele is associated with lactase persistence in some populations, such as East Africans and certain Middle Eastern groups. This SNP also functions as a regulatory element influencing LCT gene expression.




Figure 50: MCM gene organization. uploaded by [Eric Sibley](https://www.researchgate.net/publication/312222222).

VI.5.3. Technique Used for Diagnosis

Several genetic techniques are employed to diagnose lactase persistence:

1. **Genotyping Assays:** These assays are designed to detect specific SNPs associated with lactase persistence, such as -13910C>T and -22018G>A. Techniques include PCR-based methods such as restriction fragment length polymorphism (RFLP) analysis and real-time PCR with allele-specific probes. These methods are rapid and accurate for determining lactase persistence status.
2. **DNA Sequencing:** Sanger sequencing or next-generation sequencing (NGS) can be used to sequence the regulatory region upstream of the LCT gene to identify the presence of lactase persistence-associated SNPs. This approach provides precise information about the genetic variants influencing lactase expression.
3. **Haplotype Analysis:** Haplotype analysis involves examining the combination of genetic variants across a region to determine the presence of lactase persistence alleles. This can be particularly useful in populations with diverse genetic backgrounds where multiple variants may influence lactase persistence.
4. **Lactose Tolerance Test:** Although not a direct genetic test, this clinical test measures blood glucose levels after lactose ingestion to assess lactase activity. It can be used in conjunction with genetic testing to confirm the diagnosis of lactase persistence or non-persistence.

VI.6. CHARGE syndrome

VI.6.1. Description

CHARGE syndrome is a complex genetic disorder that affects multiple systems of the body. The acronym CHARGE stands for Coloboma, Heart defects, Atresia choanae, Restricted growth and development, Genital abnormalities, and Ear anomalies, which are the primary features of the syndrome. Children with CHARGE syndrome often have vision and hearing impairments, congenital heart defects, breathing and feeding difficulties due to choanal atresia (blockage of nasal passages), developmental delays, and distinct facial features. The severity and combination of symptoms can vary widely among affected individuals. Early diagnosis and multidisciplinary management are crucial for improving the quality of life for those with CHARGE syndrome.

VI.6.2. Genetic Description

CHARGE syndrome is primarily caused by mutations in the CHD7 gene (Figure 51), which plays a critical role in chromatin remodeling and regulation of gene expression during embryonic development. The inheritance pattern is typically autosomal dominant, meaning a single copy of the mutated gene can cause the disorder. However, most cases arise from de novo mutations (new mutations not inherited from parents). Key genetic aspects include:

1. **CHD7 Mutations:** The CHD7 (chromodomain helicase DNA-binding protein 7) gene, located on chromosome 8q12.1, is responsible for most cases of CHARGE syndrome. Mutations can be missense, nonsense, frameshift, or splice site mutations, leading to a loss of function of the CHD7 protein. These mutations disrupt normal developmental processes, resulting in the diverse clinical features of CHARGE syndrome.
2. **Genetic Testing and Variability:** While CHD7 mutations account for the majority of CHARGE syndrome cases, there is considerable phenotypic variability. Some patients may not have detectable mutations in CHD7, suggesting possible involvement of other genetic factors or loci.




Figure 51: CHD7 mutations. CHD7 database.

VI.6.3. Technique Used for Diagnosis

Several advanced genetic techniques are used to diagnose CHARGE syndrome:

1. **Sanger Sequencing:** This method is used to sequence the CHD7 gene to identify point mutations, small insertions, and deletions. Sanger sequencing is highly accurate and is often the first step in confirming a clinical diagnosis of CHARGE syndrome.

2. **Next-Generation Sequencing (NGS):** NGS provides a comprehensive analysis of the CHD7 gene and can detect a wide range of mutations, including those that might be missed by Sanger sequencing. NGS can also be part of broader gene panels for developmental disorders, providing additional diagnostic insights.
3. **Multiplex Ligation-dependent Probe Amplification (MLPA):** MLPA is used to detect larger deletions or duplications in the CHD7 gene that may not be identified by sequencing methods. This technique involves the hybridization of probes to target sequences, followed by ligation and amplification, to identify copy number variations.
4. **Array Comparative Genomic Hybridization (aCGH):** aCGH can detect larger genomic deletions or duplications encompassing the CHD7 gene. This technique compares the patient's DNA to a reference genome to identify variations in DNA copy number.
5. **Clinical Diagnostic Criteria:** In addition to genetic testing, clinical diagnosis is based on the presence of key features such as coloboma, heart defects, choanal atresia, and ear abnormalities. A combination of clinical evaluation and genetic testing provides the most accurate diagnosis.

VI.7. Breast cancer

VI.7.1. Description

Breast cancer is a malignant tumor that originates in the cells of the breast. It is the most common cancer among women worldwide and can also occur in men, though much less frequently. Breast cancer typically starts in the ducts (ductal carcinoma) or lobules (lobular carcinoma) of the breast tissue. Key risk factors include genetic mutations, family history, age, hormonal factors, and lifestyle choices. Symptoms of breast cancer may include a lump in the breast, changes in breast shape or size, skin dimpling, nipple discharge, and pain. Early detection through screening, such as mammography, significantly improves the chances of successful treatment, which may involve surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy.

VI.7.2. Genetic Description

Breast cancer can be sporadic or hereditary. Hereditary breast cancer is often associated with mutations in specific genes (Figure 52) that increase the risk of developing the disease.




Figure 52: Hereditary of breast cancer. Uploaded by [Martin Bak](#).

Two key genetic markers associated with hereditary breast cancer include:

- BRCA1 Mutations:** (Figure 53) The BRCA1 (Breast Cancer 1) gene, located on chromosome 17q21, is a tumor suppressor gene that plays a crucial role in DNA repair. Mutations in BRCA1 significantly increase the risk of developing breast and ovarian cancers. BRCA1 mutation carriers have a lifetime breast cancer risk of up to 65%.
- BRCA2 Mutations:** The BRCA2 (Breast Cancer 2) gene, located on chromosome 13q13, also functions in DNA repair. Similar to BRCA1, mutations in BRCA2 greatly elevate the risk of breast and ovarian cancers. The lifetime breast cancer risk for BRCA2 mutation carriers is up to 45%.




Figure 53: BRCA1, BRCA2 mutations (Dolores Gallardo-Rincón et al. 2020)

VI.7.3. Technique Used for Diagnosis

Several genetic techniques are used for diagnosing breast cancer and identifying individuals at high risk due to hereditary mutations:

1. **Genetic Testing for BRCA1 and BRCA2:** Genetic testing involves analyzing the BRCA1 and BRCA2 genes for mutations. Techniques include Sanger sequencing and Next-Generation Sequencing (NGS). These methods identify point mutations, small insertions, deletions, and larger genomic rearrangements.
 - **Sanger Sequencing:** This method sequences specific regions of the BRCA1 and BRCA2 genes to detect mutations. It is highly accurate and often used to confirm known mutations.
 - **Next-Generation Sequencing (NGS):** NGS provides a comprehensive analysis of the BRCA1 and BRCA2 genes, enabling the detection of a wide range of mutations, including novel or rare variants. NGS can be part of broader gene panels for hereditary cancer syndromes.
2. **Multiplex Ligation-dependent Probe Amplification (MLPA):** MLPA is used to detect large deletions or duplications in the BRCA1 and BRCA2 genes that may not be identified by sequencing. This technique involves the hybridization of probes to target sequences, followed by ligation and amplification to identify copy number variations.

3. **Array Comparative Genomic Hybridization (aCGH):** aCGH can identify larger genomic deletions or duplications encompassing the BRCA1 or BRCA2 loci. This technique compares the patient's DNA to a reference genome to detect variations in DNA copy number.
4. **Tumor Genomic Profiling:** For patients with breast cancer, genomic profiling of the tumor can provide information on somatic mutations, which can guide targeted therapy. Techniques such as NGS are used to identify actionable mutations in the tumor DNA.
5. **Clinical Diagnostic Criteria and Family History Assessment:** In addition to genetic testing, a detailed family history and assessment of clinical criteria are crucial for identifying individuals at risk of hereditary breast cancer. Genetic counseling is recommended for individuals undergoing genetic testing to understand the implications of the results.

VI.8. Crohn's disease

VI.8.1. Description

Crohn's disease is a chronic inflammatory bowel disease (IBD) characterized by inflammation of the gastrointestinal (GI) tract, which can affect any part from the mouth to the anus. The inflammation often spreads deep into the layers of the affected bowel tissue, leading to a range of symptoms including abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The exact cause of Crohn's disease is unknown, but it is believed to involve a combination of genetic (Figure 54), environmental, and immune factors. The disease can be debilitating and may lead to life-threatening complications such as bowel obstruction, fistulas, and colorectal cancer. Treatment typically focuses on reducing inflammation, managing symptoms, and maintaining remission through medications, lifestyle changes, and sometimes surgery.




Figure 54: NOD2 associates Crohn's disease. By Frontiers.

VI.8.2. Genetic Description

Crohn's disease has a significant genetic component, with several genes implicated in increasing susceptibility to the condition. Two key genetic markers associated with Crohn's disease include:

1. **NOD2/CARD15 Mutations:** The NOD2 (nucleotide-binding oligomerization domain 2) gene, also known as CARD15 (caspase recruitment domain family member 15), located on chromosome 16q12.1, is one of the most well-studied genes linked to Crohn's disease. Mutations in NOD2 (Figure 55) are associated with an increased risk of developing Crohn's disease, particularly in the ileum. These mutations impair the gene's ability to recognize bacterial molecules and activate an appropriate immune response, leading to chronic inflammation.




Figure 55: NOD2 gene organization. Uploaded by [Ma Isabel Salazar](#).

2. **ATG16L1 and IRGM Genes:** Variants in the ATG16L1 (autophagy-related 16-like 1) gene and the IRGM (immunity-related GTPase M) gene are also linked to Crohn's disease. These genes are involved in the process of autophagy, which is crucial for the elimination of intracellular pathogens and the regulation of the immune response. Variants in these genes can affect the body's ability to control intestinal bacteria, contributing to the inflammation seen in Crohn's disease.

VI.8.3. Technique Used for Diagnosis

Several genetic and clinical techniques are used for diagnosing Crohn's disease and identifying genetic predispositions:

1. **Genetic Testing:** Genetic testing for Crohn's disease often involves analyzing specific genes known to be associated with the condition, such as NOD2, ATG16L1, and IRGM. Techniques include:
 - **Next-Generation Sequencing (NGS):** This method provides a comprehensive analysis of multiple genes simultaneously, detecting a wide range of mutations, including single nucleotide polymorphisms (SNPs), insertions, deletions, and rare variants.
 - **Sanger Sequencing:** Used for sequencing specific regions of interest within the genes associated with Crohn's disease, providing high accuracy for detecting known mutations.
2. **Serological Tests:** Blood tests can detect specific antibodies (e.g., anti-Saccharomyces cerevisiae antibodies, ASCA) that are often elevated in Crohn's disease, although they are not definitive for diagnosis.

VII. Advances in Disease Gene Identification

VII.1. Alzheimer disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and behavioral changes. Over the years, significant advancements in genetic research have deepened our understanding of the genetic underpinnings of Alzheimer's disease. These advances have been instrumental in identifying several genes and genetic risk factors associated with the disease (Figure 56):

1. **APOE Gene:** The APOE (Apolipoprotein E) gene remains the strongest genetic risk factor for late-onset Alzheimer's disease (LOAD). The APOE gene has three common alleles: $\epsilon 2$, $\epsilon 3$, and $\epsilon 4$. The $\epsilon 4$ allele is associated with an increased risk of developing Alzheimer's disease, while the $\epsilon 2$ allele may have a protective effect. The presence of one or two copies of the $\epsilon 4$ allele influences the age of onset and severity of the disease.




Figure 56: Abnormal cleavage of amyloid precursor protein. uploaded by Ging-Yuek Robin Hsiung.

2. **APP, PSEN1, and PSEN2 Genes:** Mutations in the APP (Amyloid Precursor Protein), PSEN1 (Presenilin 1), and PSEN2 (Presenilin 2) genes cause rare, early-onset familial forms of Alzheimer's disease (Figure 57). These genes are involved in the production and processing of amyloid beta (Aβ) protein, a key component of amyloid plaques found in the brains of Alzheimer's patients. Mutations in these genes lead to increased production of Aβ42, which aggregates and forms plaques, contributing to neurodegeneration.




Figure 57: PSEN 1,2 mutations.

3. **GWAS Findings:** Genome-wide association studies (GWAS) have identified numerous common genetic variants associated with increased susceptibility to late-onset Alzheimer's disease. These variants are located in or near genes involved in immune response, lipid metabolism, and synaptic function. Examples include variants near CLU (Clusterin), CR1 (Complement Receptor 1), and TREM2 (Triggering Receptor Expressed on Myeloid cells 2), which play roles in inflammation, synaptic pruning, and immune response in the brain.

4. **Rare Variants and Next-Generation Sequencing (NGS):** Advances in NGS technologies have facilitated the discovery of rare variants and mutations in genes that confer risk for Alzheimer's disease. Whole-exome sequencing and whole-genome sequencing studies have identified novel genes and pathways involved in disease pathogenesis, expanding our understanding beyond the well-known genes like APOE and APP.

5. **Polygenic Risk Scores (PRS):** PRS, calculated based on the cumulative effects of multiple genetic variants identified through GWAS, provide personalized risk assessments for Alzheimer's disease. PRS integrate genetic data from thousands of variants to predict an individual's likelihood of developing the disease, offering potential applications in early detection and personalized treatment strategies.

6. **Functional Genomics and Systems Biology:** Functional genomics studies, including transcriptomics, proteomics, and epigenomics, have provided insights into the molecular mechanisms underlying Alzheimer's disease. These studies have identified dysregulated pathways, protein interactions, and epigenetic modifications associated with disease progression, highlighting new therapeutic targets.

VII.2. Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration (AMD) is a progressive eye condition affecting the macula, the central part of the retina responsible for sharp, central vision. It is a leading cause of vision loss among older adults. Advances in genetic research have significantly enhanced our understanding of the genetic factors contributing to AMD:

1. **Complement Factor H (CFH) Gene:** One of the earliest and most significant genetic findings in AMD is the association with variants in the CFH gene on chromosome 1 (Figure 58). Specifically, the rs1061170 variant (also known as Y402H) is strongly associated with an increased risk of developing AMD. CFH is involved in the regulation of the complement system, which plays a role in inflammation and immune response in the retina.




Figure 58: Complement Factors pathway. (*Cancers* 2022).

2. **ARMS2 (Age-Related Maculopathy Susceptibility 2) Gene:** Variants in the ARMS2 gene, particularly the rs10490924 variant, have been identified as significant genetic risk factors for AMD (Figure 59). ARMS2 is located on chromosome 10 and its function is still under investigation, but it is thought to be involved in mitochondrial function and oxidative stress in the retina.




Figure 59: ARMS2 gene organization. Upload by nature 2008.

3. **HTRA1 (High-Temperature Requirement A Serine Peptidase 1) Gene:** Variants near the HTRA1 gene on chromosome 10 have also been implicated in AMD susceptibility, particularly in Asian populations. HTRA1 encodes a serine protease involved in extracellular matrix remodeling and regulation of cell growth (Figure 60).




Figure 60: HTRA1 pathway. Upload by pathway signalization nature

4. **Genome-Wide Association Studies (GWAS):** GWAS have identified numerous other genetic variants associated with AMD across different populations. These studies have highlighted genes involved in lipid metabolism, immune response, and extracellular matrix regulation, such as C3, C2/CFB, and COL8A1.

5. **Rare and Structural Variants:** Next-generation sequencing (NGS) technologies have enabled the discovery of rare and structural variants associated with AMD. Whole-exome sequencing and whole-genome sequencing studies have identified novel genes and pathways involved in disease pathogenesis, expanding our understanding beyond the well-established risk loci.

6. **Polygenic Risk Scores (PRS):** PRS, calculated based on the cumulative effects of multiple genetic variants identified through GWAS, provide personalized risk assessments for AMD. These scores integrate genetic data to predict an individual's likelihood of developing AMD, aiding in early detection and personalized treatment strategies.

7. **Functional Genomics and Pathway Analysis:** Functional genomics studies, including transcriptomics and proteomics, have elucidated the biological mechanisms underlying AMD. These studies have identified dysregulated pathways, protein interactions, and molecular signatures associated with disease progression, offering potential targets for therapeutic intervention.

VII.3. Eczema (atopic dermatitis)

Eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition characterized by itching, redness, and skin lesions. It often begins in infancy or childhood and

can persist into adulthood. Genetic research has played a crucial role in unraveling the underlying factors contributing to eczema. Here are some key advances in understanding the genetic basis of eczema:

1. **Filaggrin (FLG) Gene:** One of the most significant genetic findings in eczema is mutations in the Filaggrin gene (FLG). FLG encodes a protein that plays a critical role in maintaining the skin barrier function. Loss-of-function mutations in FLG are associated with impaired skin barrier integrity, leading to increased susceptibility to eczema and other allergic conditions.

2. **Genome-Wide Association Studies (GWAS):** GWAS have identified multiple genetic variants associated with eczema susceptibility. These studies have highlighted genes involved in immune regulation, skin barrier function, and inflammatory pathways. Variants in genes such as IL4, IL13, IL31RA, and SPINK5 have been linked to eczema risk.

3. **Th2 and Th17 Pathways:** Eczema is characterized by dysregulated immune responses, particularly involving Th2 and Th17 cytokines. Genetic studies have elucidated how variants in genes regulating these pathways contribute to the inflammatory processes seen in eczema. This includes genes encoding cytokines, cytokine receptors, and transcription factors critical for immune cell differentiation and activation.

4. **Epigenetics:** Research into epigenetic modifications, such as DNA methylation and histone modifications, has provided insights into how environmental factors influence gene expression in eczema. Epigenetic changes can alter immune responses and skin barrier function, contributing to disease susceptibility and severity.

5. **Gene-Environment Interactions:** Genetic susceptibility to eczema often interacts with environmental factors, such as allergens, irritants, and microbial exposures. Understanding these interactions is crucial for identifying individuals at higher risk and developing targeted prevention strategies.

6. **Personalized Medicine Approaches:** Advances in genetic testing and personalized medicine hold promise for improving eczema management. Genetic profiling may help identify subtypes of eczema with specific genetic drivers, guiding personalized treatment strategies tailored to individual patients.

7. **Biological Therapies:** Insights from genetic research have spurred the development of biological therapies targeting specific immune pathways implicated in eczema. These

therapies aim to modulate immune responses and restore skin barrier function, offering new treatment options for patients with severe or treatment-resistant eczema.

Chapter II: Cancer Genetics

I. Cancer Development

Cancer is a complex group of diseases characterized by abnormal cell growth (Figure 61) that can invade and spread to other parts of the body. It is one of the leading causes of death worldwide, impacting millions of individuals annually.




Figure 61: Development of malignant tumor. IHH Healthcare singapore, 2018.

Cancer is a multifaceted disease driven by a combination of environmental and genetic factors. Environmental influences, which account for an estimated 70-90% of cancer cases, include lifestyle factors such as smoking, diet, and physical activity. For instance, tobacco smoking is linked to approximately 22% of cancer deaths globally, making it the most significant preventable cause of cancer. Diet and physical inactivity contribute to about 30-35% of cancer deaths, while infections (e.g., human papillomavirus, hepatitis B and C) account for around 15-20%.

On the genetic front, inherited mutations are responsible for about 5-10% of all cancers. Specific genes, like BRCA1 and BRCA2, are well-known for their role in increasing the risk of breast and ovarian cancers, with carriers facing up to a 65% lifetime risk of breast cancer, compared to 12% in the general population. Lynch syndrome, another genetic condition, elevates the risk of colorectal cancer significantly, with affected individuals having up to a 70% lifetime risk compared to about 4.5% in the general population.

The interplay between genetic susceptibility and environmental exposures is crucial (Figure 62). For example, individuals with a genetic predisposition to lung cancer due to

polymorphisms in certain genes might be more susceptible to the harmful effects of smoking. This synergy highlights the importance of both genetic screening and lifestyle modifications in cancer prevention and management. Understanding these complex interactions is essential for developing targeted prevention strategies, improving early detection, and tailoring treatments to individual risk profiles.




Figure 62: Cancer etiology.

Cancer can arise from almost any tissue or organ in the body and is categorized based on its site of origin, histological features, and genetic alterations. Here's an overview covering its explanation, and localization.

Cancer begins when cells in a part of the body start to grow out of control (Figure 63). Normal cells grow, divide, and die in a controlled manner to maintain tissue health. Cancerous cells, however, evade this normal growth regulation. They can continue to grow and divide uncontrollably, forming a mass called a tumor. Cancerous tumors can invade nearby tissues and organs, and cancer cells can also break away from the original tumor to spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.




Figure 63: Normal and cancer cell division. uploaded by [Vicente Mendoza Reyes](#).

Cancer can be broadly categorized into sporadic and hereditary types (Figure 64), each with distinct characteristics and implications. Sporadic cancers, which constitute about 85-90% of all cancer cases, arise from genetic mutations that accumulate over a person's lifetime due to environmental factors such as tobacco use, diet, radiation, and infections, or due to random errors during cell division. These mutations are not inherited but occur in somatic cells, meaning they are not passed down to offspring. In contrast, hereditary cancers, which make up about 5-10% of all cases, result from inherited genetic mutations that significantly increase an individual's risk of developing cancer. These mutations are present in germline cells and can be passed from parents to children. Notable examples include mutations in the BRCA1 and BRCA2 genes, which markedly elevate the risk of breast and ovarian cancers, and mutations associated with Lynch syndrome, which increase the risk of colorectal and other cancers. Individuals with hereditary cancer syndromes often develop cancer at a younger age and may have multiple relatives affected by similar cancers. Understanding the distinction between sporadic and hereditary cancers is crucial for effective prevention, early detection, and personalized treatment strategies.




Figure 64: Sporadic and heredity form of cancer.

Cancer classification is a systematic approach to categorize different types of cancers based on various criteria such as tissue of origin, histological characteristics, molecular features, and clinical behavior. This classification helps oncologists and healthcare professionals understand the nature of cancer, predict its behavior, guide treatment decisions, and determine prognosis. Key categories include:

a. Tissue of Origin

Cancers classified by the type of tissue from which they originate, such as epithelial cells (carcinomas), connective tissues (sarcomas), blood-forming tissues (leukemias), and lymphatic tissues (lymphomas).

b. Histological Classification

Cancers classified by their microscopic appearance, including adenocarcinomas (glandular tissue), squamous cell carcinomas (squamous epithelial cells), and poorly differentiated tumors.

c. Molecular and Genetic Classification

Cancers classified based on specific genetic mutations, molecular alterations, and biomarkers that influence cancer development, progression, and response to treatment.

d. Clinical Classification

Cancers categorized by clinical characteristics such as stage (extent of spread), grade (aggressiveness of cancer cells), and other clinical features that impact prognosis and treatment decisions.

II. Cancer etiology

II.1. Viral Infection Pathway

Viral infections can contribute to cancer development through multiple mechanisms, and understanding these pathways is essential for developing targeted interventions (Figure 65). Certain viruses have oncogenic properties, meaning they can induce cancer by altering cellular mechanisms. They can integrate their genetic material into the host's DNA, leading to the disruption of genes that control cell growth and division. This integration can activate oncogenes, which promote cell proliferation, or inactivate tumor suppressor genes, which normally function to prevent uncontrolled cell growth. Additionally, some viruses cause chronic inflammation, which generates a pro-tumorigenic environment by continuously stimulating cell division and creating opportunities for genetic mutations.




Figure 65: Viral infections involved on cancer. Available via license: [CC BY 3.0](https://creativecommons.org/licenses/by/3.0/)

Human papillomavirus (HPV) is a well-known example of an oncogenic virus. HPV produces proteins like E6 and E7, which interfere with the functions of p53 and Rb, two crucial tumor suppressor proteins. This interference leads to unchecked cellular proliferation and eventually cancer, particularly cervical cancer, but also cancers of the oropharynx, anus, and penis.

Another significant example is the Human T-cell leukemia virus type 1 (HTLV-1), a human retrovirus that causes adult T-cell leukemia/lymphoma (ATLL). HTLV-1 integrates its RNA genome into the host's DNA using the enzyme reverse transcriptase. This integration disrupts

normal cellular functions by altering gene expression and promoting the proliferation of infected T-cells. The viral protein Tax plays a crucial role in this process by activating transcription factors and signaling pathways that drive cell proliferation and inhibit apoptosis (programmed cell death), leading to the transformation of T-cells into cancerous cells.

The Epstein-Barr virus (EBV) is another example, linked to Burkitt's lymphoma, Hodgkin's lymphoma, and nasopharyngeal carcinoma. EBV infects B-cells and can drive their uncontrolled proliferation through proteins like LMP1, which mimics a constitutively active receptor, activating growth-promoting pathways.

II.2. Viral Infection Pathway

Cytogenetic abnormalities, which involve changes in the structure or number of chromosomes, play a critical role in the development of cancer. These abnormalities can lead to the activation of oncogenes or the inactivation of tumor suppressor genes, thereby promoting uncontrolled cell growth and malignancy. Structural changes such as translocations, deletions, amplifications, and inversions can disrupt normal genetic function. Numerical changes, like aneuploidy (abnormal number of chromosomes), can also contribute to cancer by causing genomic instability and altering gene expression patterns.

A well-known example of a cytogenetic abnormality in cancer is the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22, specifically $t(9;22)(q34;q11)$ (Figure 66). This translocation creates the BCR-ABL fusion gene, which encodes a constitutively active tyrosine kinase. The BCR-ABL protein continuously signals cells to proliferate and evade apoptosis, leading to chronic myeloid leukemia (CML). Targeted therapy with tyrosine kinase inhibitors, such as imatinib, has been highly effective in treating CML by specifically inhibiting the BCR-ABL protein's activity.




Figure 66: Philadelphia chromosome. National cancer institutt, 2024.

Another example involves the c-MYC gene, which is frequently altered in various cancers. The c-MYC gene, located on chromosome 8, can become dysregulated through translocations, amplifications, or other genetic alterations. In Burkitt's lymphoma, a translocation between chromosomes 8 and 14, $t(8;14)(q24;q32)$, places the c-MYC gene under the control of the immunoglobulin heavy chain promoter, leading to its overexpression (Figure 67). This overexpression drives rapid cell division and contributes to the aggressive nature of Burkitt's lymphoma.




Figure 67: c. myc pathway. By Yilei Deng, 2024

II.3. Molecular genetic mutation

Molecular genetic mutations are critical drivers of cancer, involving alterations in the DNA sequence that affect gene function. These mutations can be point mutations, insertions, deletions, or more complex genetic rearrangements, leading to the activation of oncogenes or the inactivation of tumor suppressor genes. Such genetic changes disrupt normal cell cycle regulation, apoptosis, and DNA repair mechanisms, resulting in uncontrolled cell proliferation and cancer development.

An illustrative example of a molecular genetic mutation in cancer involves the RAS family of genes, which includes KRAS, NRAS, and HRAS. These genes encode small GTPase proteins that play a pivotal role in cell signaling pathways regulating growth, differentiation, and survival. Mutations in RAS genes, particularly KRAS, are among the most common oncogenic mutations in human cancers. KRAS mutations are found in approximately 30% of all cancers, including a high percentage of pancreatic (about 90%), colorectal (about 40%), and lung adenocarcinomas (about 30%).

The most frequent mutations in KRAS occur at codons 12, 13, and 61, leading to a constitutively active protein that is perpetually "on," regardless of extracellular signals (Figure 68). This aberrant activation continuously stimulates downstream signaling pathways, such as the MAPK and PI3K-AKT pathways, promoting cell proliferation and survival while preventing apoptosis. The persistence of these signals drives the transformation of normal cells into cancerous ones and supports the growth and maintenance of tumors.




Figure 68: Ras pathway. by [Aaron Hua](#), 2024.

III. Oncogenes

An oncogene is a gene that, when mutated or overexpressed, has the potential to drive the development of cancer. Normally, these genes, known as proto-oncogenes, play crucial roles in regulating cell growth, differentiation, and survival. However, mutations or alterations in proto-oncogenes can transform them into oncogenes (Figure 69), which can then promote uncontrolled cell proliferation and contribute to tumor formation. The activation of oncogenes can occur through several mechanisms, including point mutations that lead to a gain-of-function in the encoded protein, gene amplification resulting in an increased number of copies of the oncogene, chromosomal rearrangements that fuse regulatory elements with the coding sequence of the oncogene, or viral integration into the host genome. Once activated, oncogenes can dysregulate signaling pathways involved in cell cycle progression, apoptosis, angiogenesis, and metastasis, thereby driving the hallmarks of cancer. Examples of well-known oncogenes include HER2 (Human Epidermal Growth Factor Receptor 2), KRAS (Kirsten Rat Sarcoma viral oncogene homolog), and MYC (v-Myc Avian Myelocytomatosis Viral Oncogene Homolog).




Figure 69: Proto oncogene and oncogene.

Targeting oncogenic pathways has become a cornerstone of modern cancer therapy, with specific inhibitors designed to block the aberrant activity of oncogenes and improve patient outcomes through personalized treatment approaches.

IV. Tumor Suppressor Genes

Tumor suppressor genes, also known as anti-oncogenes, play a pivotal role in safeguarding cellular integrity and preventing the onset of cancer (Figure 70). These genes act as natural inhibitors of tumorigenesis by regulating cell growth, repairing damaged DNA, and promoting the orderly death of cells when necessary. They function through various mechanisms, including halting cell cycle progression, initiating DNA repair pathways, inducing apoptosis in damaged or abnormal cells, and maintaining proper cell adhesion within tissues. Loss-of-function mutations or deletions in tumor suppressor genes can impair their normal function, leading to unchecked cell proliferation and the accumulation of genetic errors that contribute to cancer development. Examples of well-characterized tumor suppressor genes include TP53 (p53), BRCA1, PTEN, and RB1. Understanding the role of tumor suppressor genes is crucial for devising targeted therapies aimed at restoring their function or compensating for their loss, thereby potentially halting or reversing the progression of cancer in affected individuals.





Figure 70: Anti-oncogene.

V. Dysregulation of Cell Cycle Control in Cancer

Dysregulation of cell cycle control is a fundamental characteristic of cancer cells, allowing them to evade normal growth constraints and proliferate uncontrollably. The cell cycle consists of phases (G1, S, G2, and M) regulated by cyclin-dependent kinases (CDKs) and their partner cyclins, which coordinate progression through checkpoints that monitor DNA integrity and cell size before allowing division. In cancer, mutations in oncogenes like MYC or RAS can lead to overactivation of CDKs, promoting continuous cell cycle progression even in the absence of growth signals. Conversely, loss-of-function mutations in tumor suppressor genes such as p53 or RB can impair cell cycle arrest mechanisms, allowing cells with damaged DNA to replicate and accumulate mutations. Targeting dysregulated cell cycle pathways is a major focus of

cancer therapy, with inhibitors of CDKs (e.g., palbociclib, ribociclib) designed to induce cell cycle arrest and apoptosis specifically in cancer cells while sparing normal cells.

MYC Gene: The MYC gene is a proto-oncogene that encodes the c-Myc protein, a transcription factor involved in the regulation of cell growth and proliferation (Figure 71). In its normal state, MYC plays a critical role in cell cycle progression by promoting the expression of genes necessary for cell division.



However, dysregulation of MYC, often through amplification or overexpression due to genetic alterations or upstream signaling events, can lead to oncogenic transformation. For example, in many types of cancers, including Burkitt lymphoma and some forms of breast cancer, MYC is frequently amplified or overexpressed. This overactivation results in sustained cell cycle progression, increased cell proliferation, and resistance to apoptosis, contributing to tumor growth and progression. Targeted therapies aimed at inhibiting MYC or its downstream effectors are actively being researched as potential treatments for MYC-driven cancers.

VI. Genome Instability

Genome instability is a hallmark of cancer that profoundly influences its initiation, progression, and therapeutic response. This instability encompasses a spectrum of genetic alterations, including mutations, chromosomal rearrangements, and changes in DNA copy number, which collectively contribute to the genetic diversity observed within tumors. By promoting mutagenesis, genome instability increases the likelihood of acquiring oncogenic mutations in genes regulating cell growth, apoptosis, and DNA repair pathways. This genetic diversity fuels tumor heterogeneity, enabling the emergence of subpopulations of cancer cells that possess survival advantages, such as resistance to chemotherapy or immune evasion. Moreover, genome instability can activate oncogenes through amplification or structural rearrangements, while simultaneously inactivating tumor suppressor genes critical for maintaining genomic integrity. These alterations disrupt normal cellular functions, drive uncontrolled cell proliferation, and facilitate the metastatic spread of cancer cells to distant

organs. Understanding the complex interplay between genome instability and cancer progression is essential for developing targeted therapies aimed at exploiting vulnerabilities associated with genomic alterations, thereby improving treatment outcomes and patient survival. The FLT3 seems to be a perfect example.

FLT3 Gene: The FLT3 gene (FMS-like tyrosine kinase 3) encodes a receptor tyrosine kinase involved in normal hematopoiesis and immune cell function (Figure 72). Mutations in FLT3, particularly internal tandem duplications (ITDs) in the juxtamembrane domain or point mutations in the tyrosine kinase domain, are commonly found in acute myeloid leukemia (AML).




Figure 72: The FLT3 gene. Boold cancer review, 2022.

These mutations result in constitutive activation of FLT3 signaling pathways, leading to dysregulated cell proliferation and survival. In AML patients with FLT3-ITD mutations (Figure 73), the aberrant FLT3 signaling promotes continuous activation of CDKs and other cell cycle regulatory proteins, driving uncontrolled cell division and leukemic transformation. Targeted inhibitors of FLT3, such as midostaurin and gilteritinib, have been developed to specifically block FLT3 activity and disrupt downstream cell cycle pathways, thereby inducing apoptosis and reducing tumor burden in FLT3-mutated AML.




Figure 73: Flt3 mutations. NITIKA, *Cancers* 2022.

VII. Cancer and Whole Genome Studies

Whole genome studies have revolutionized our understanding of cancer biology by enabling comprehensive analysis of the entire genetic blueprint of cancer cells. This approach, often using techniques like whole genome sequencing (WGS), allows researchers to uncover a wealth of genetic alterations, including mutations, copy number variations, and structural rearrangements, that drive oncogenesis and tumor progression. Example of RB Gene and TP53 Gene:

RB Gene (Retinoblastoma Gene):

The RB gene is a classic tumor suppressor gene that regulates the cell cycle by inhibiting the activity of E2F transcription factors, thereby controlling the progression from G1 to S phase. Loss-of-function mutations or deletions in the RB gene disrupt this regulatory function, leading to uncontrolled cell cycle progression and increased cell proliferation. Such alterations are commonly found in retinoblastoma, a rare eye cancer that typically affects young children. Whole genome studies have identified mutations in the RB gene and other genes involved in cell cycle regulation as key drivers of retinoblastoma tumorigenesis (Figure 74). Understanding these genetic alterations has not only improved diagnostic accuracy but also guided the development of targeted therapies aimed at restoring RB function or exploiting vulnerabilities associated with RB-deficient tumors.




Figure 74: Rb function. uploaded by [Julien Sage](#).

TP53 Gene (p53)

The TP53 gene encodes the p53 protein, often referred to as the "guardian of the genome," which plays a central role in maintaining genomic stability and regulating cellular responses to stress, including DNA damage (Figure 75). Mutations in TP53 are among the most frequent genetic alterations observed in human cancers across various types, including breast cancer, colorectal cancer, and lung cancer. These mutations can lead to loss of p53 function, impairing its ability to activate DNA repair mechanisms or induce apoptosis in cells with irreparable DNA damage. Whole genome studies have identified specific TP53 mutations associated with cancer susceptibility, disease progression, and response to therapy. For instance, certain TP53 mutations are associated with increased resistance to chemotherapy or targeted therapies, influencing treatment decisions and patient outcomes.




Figure 75: P53 pathway. Oncotarget 2008

VIII. Understanding the Multistep Development of Tumors

Understanding the multistep development of tumors involves unraveling the complex interplay of genetic alterations that drive the progression from normal cells to malignant tumors. Genetic markers play a pivotal role in this process by identifying specific mutations, variations, or genomic characteristics associated with different stages of tumor development. Here's how genetic markers contribute to understanding the multistep development of tumors:

Early Detection and Risk Assessment: Genetic markers can be used for early detection of genetic predispositions or mutations associated with increased cancer risk. For instance, mutations in tumor suppressor genes like TP53 or RB1 may predispose individuals to certain cancers. Screening for these mutations in high-risk populations allows for early intervention and preventive measures to reduce cancer incidence.

Identification of Driver Mutations: Throughout tumor progression, genetic markers help identify driver mutations that initiate and promote cancer development. For example, mutations in oncogenes such as KRAS or BRAF can activate signaling pathways that drive cell proliferation and survival, contributing to tumor growth. By pinpointing these driver mutations, researchers can elucidate key molecular pathways involved in tumor initiation and progression.

Tracking Clonal Evolution: Genetic markers enable the tracking of clonal evolution within tumors, revealing the diversity of subclones and their contributions to tumor heterogeneity. As tumors evolve, they accumulate additional mutations and genetic alterations that confer selective advantages, such as resistance to therapies or enhanced metastatic potential. Understanding the dynamics of clonal evolution helps predict disease progression and tailor treatment strategies accordingly.

Predicting Treatment Response: Genetic markers are essential for predicting treatment response and resistance mechanisms in cancer patients. Biomarkers such as mutations in EGFR for lung cancer or HER2 amplification in breast cancer guide targeted therapies that specifically inhibit oncogenic pathways driving tumor growth. Monitoring changes in genetic markers during treatment allows clinicians to adapt therapy regimens and optimize patient outcomes.

Personalized Medicine: Advances in genetic markers contribute to personalized medicine approaches in oncology, where treatments are tailored based on the genetic profile of individual tumors. Molecular profiling of tumors using next-generation sequencing or other genomic technologies helps identify actionable mutations and select targeted therapies that are more effective and less toxic than conventional treatments.

Prognostic and Predictive Tools: Genetic markers serve as prognostic indicators by predicting the likelihood of disease recurrence or progression based on molecular characteristics of the

tumor. Additionally, they provide predictive insights into patient outcomes and survival rates, guiding clinical decision-making and patient counseling.

IX. Data Integration: Cancer in Terms of Cell Biology

Data integration in cancer research is essential for unraveling the intricate molecular underpinnings of the disease across various biological levels. By combining diverse datasets from genomics, transcriptomics, proteomics, and clinical data, researchers can construct a comprehensive landscape of cancer biology. Genomic analyses identify mutations, copy number variations, and structural alterations in cancer genomes, revealing genetic drivers of tumorigenesis and progression. Transcriptomic studies elucidate how these genetic changes manifest in altered gene expression patterns and dysregulated cellular pathways. Proteomic analyses complement these findings by identifying proteins and their modifications that contribute to cancer phenotypes. Integrating these multi-omic data sets enables the identification of biomarkers for early detection, prognosis, and prediction of treatment response. Moreover, advanced computational methods and systems biology approaches facilitate the modeling and simulation of complex biological networks and pathways affected by cancer, providing insights into disease mechanisms and guiding the development of targeted therapies. Ultimately, data integration accelerates our understanding of cancer biology and supports the advancement of precision medicine approaches tailored to individual patients, aiming to improve outcomes and reduce the burden of cancer worldwide

References

- Artal-Sanz, M., & Tavernarakis, N. (2009). Prohibitin couples diapause signalling to mitochondrial metabolism during ageing in *C. elegans*. *Nature*, 461(7265), 793-797.
- Baumeister, R., & Klassen, S. (2010). The nematode *Caenorhabditis elegans*: a versatile model organism for biomedical research. In *The Laboratory Rat* (pp. 151-176). Academic Press.
- Flibotte, S., Edgley, M. L., Chaudhry, I., Taylor, J., Neil, S. E., Rogula, A., ... & Moerman, D. G. (2010). Whole-genome profiling of mutagenesis in *Caenorhabditis elegans*. *Genetics*, 185(2), 431-441.
- Hillier, L. W., Coulson, A., Murray, J. I., Bao, Z., Sulston, J. E., & Waterston, R. H. (2005). Genomics in *C. elegans*: so many genes, such a little worm. *Genome Research*, 15(12), 1651-1660.
- Hodgkin, J., & Brenner, S. (1977). Mutations causing transformation of sexual phenotype in the nematode *Caenorhabditis elegans*. *Genetics*, 86(2 Pt. 1), 275-287.
- HW Mewes, K Albermann, M Bähr, D Frishman (1997) Overview of the yeast genome. *Nature* ; 389 (27)
- Kamath, R. S., Fraser, A. G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., ... & Ahringer, J. (2003). Systematic functional analysis of the *Caenorhabditis elegans* genome using RNAi. *Nature*, 421(6920), 231-237.
- Malik H.S et Henikoff S. Phylogenomics of the nucleosome. *Nat Struc Biol.* 2003, 10:882-891.
- Malone, C.J., Fixsen, W.D., Horvitz, H.R. and Han, M. UNC-84 localizes to the nuclear envelope and is required for nuclear migration and anchoring during *C. elegans* development. *Development.* 1999, 126: 3171-3181.
- Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., ... & Evans, R. M. The nuclear receptor superfamily: the second decade. *Cell.* 1995, 83(6): 835-839.
- Mani U, Sankareswaran S A, Goutham R. N A, Mohan S S. SWI/SNF Infobase—An exclusive information portal for SWI/SNF remodeling complex subunits. *PLoS One.* 2017; 12(9): e0184445
- Mansharamani, M. and Wilson, K.L. Direct binding of nuclear membrane protein MAN1 to emerlin in vitro and two modes of binding to barrier-to-autointegration factor. *J Biol Chem.* 2005, 280 : 13863-13870.
- Margueron R, Trojer P et Reinberg D. The key to development: interpreting the histone code? *Curr Opin Genet Dev.*2005, 15:163-176.
- Markiewicz, E., Dechat, T., Foisner, R., Quinlan, R.A. and Hutchison, C.J. Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of retinoblastoma protein. *Mol Biol Cell.* 2002, 13: 4401-4413.
- Schultz D.C, Friedman J.R et Rauscher III F.J. Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD. *Genes Dev.* 2001, 15:428-443.
- Shandilya J et Roberts S.G. The transcription cycle in eukaryotes: from peoductive initiation to RNA polymerase II recycling. *BBA.* 2012, 1819:391-400.
- Shang Y, Hu X, Di Renzo J, Lazar M.A et Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell* 103:843-852. *J Cell Sci.* 2000, 119:4101-4116.

- Shaulian, E., & Karin, M. AP-1 in cell proliferation and survival. *Oncogene*. 2002, 20(19): 2390-2400.
- Shen X, Mizuguchi G, Hamiche A et Wu C. A chromatin remodeling complex involved in transcription and DNA processing. *Nature*. 2000, 406:541-544.
- Silve, S., Dupuy, P.H., Ferrara, P. and Loison, G. Human lamin B receptor exhibits sterol C14-reductase activity in *Saccharomyces cerevisiae*. *Biochim Biophys Acta*. 1998, 1392 : 233-244.
- Sims R.J 3rd, Mandal S.S et Reinberg D. Recent highlights of RNA-polymerase II mediated transcription. *Curr Opin Cell Biol*. 2004, 16:263-271.
- Singh B.N et Hampsey M. A transcription-independent role for TFIIB in gene looping. *Mol Cell*. 2007, 27:806-816.
- Singh M; Popowicz G.M, Krajewski M et Holak T.A. Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex. *Chem Bio Chem*. 2007, 8:1308-1316.
- Smale S.T, Jain A, Kaufmann J, Emami K.H, Lo K et Garraway I.P. The initiator element: a paradigm for core promoter heterogeneity within metazoan protein-coding genes. *Cold Spring Harb Symp Quant Biol*. 1998, 63:21-31.
- Somech, R., Shaklai, S., Amariglio, N., Rechavi, G. and Simon, A.J. Nuclear envelopathies--raising the nuclear veil. *Pediatr Res*. 2005, 57 : 8R-15R.
- Song SH, Kim TY. CTCF, Cohesin, and Chromatin in Human Cancer. *Gastrointestinal Intervention* 2017; 15(4): 114-122.
- Soullam, B. and Worman, H.J. Signals and structural features involved in integral membrane protein targeting to the inner nuclear membrane. *J Cell Biol*. 1995, 130: 15-27.
- Soullam, B. and Worman, H.J. The amino-terminal domain of the lamin B receptor is a nuclear envelope targeting signal. *J Cell Biol*. 1993, 120: 1093-1100.
- Spann, T.P., Moir, R.D., Goldman, A.E., Stick, R. and Goldman, R.D. Disruption of nuclear lamin organization alters the distribution of replication factors and inhibits DNA synthesis. *J Cell Biol*. 1997, 136 : 1201-1212.
- Spencer J.F.T., Spencer D.M., Smith A.R.W. (2012). *Yeast Genetics, Fundamental and Applied Aspects*. Springer series on molecular biology.
- Starr, D.A. and Fischer, J.A. KASH 'n Karry: the KASH domain family of cargospecific cytoskeletal adaptor proteins. *Bioessays*. 2005, 27: 1136-1146.
- Starr, D.A. and Han, M. ANChors away: an actin based mechanism of nuclear positioning. *J Cell Sci*. 2003, 116: 211-216.
- Starr, D.A. and Han, M. Role of ANC-1 in tethering nuclei to the actin cytoskeleton. *Science*. 2002, 298: 406-409.
- Stavreva D.A, Varticovski L et Hager G.L. Complex dynamics of transcription regulation. *BBA*. 2012, 1819:657-666.
- Stewart CL, Roux KJ, Burke B. Blurring the Boundary: The Nuclear Envelope Extends Its Reach. *SCIENCE*. 2007 ;318 (5855): 1408-1412.
- Stewart, C. and Burke, B. Teratocarcinoma stem cells and early mouse embryos contain only. 1987.
- Stick, R. and Hausen, P. Changes in the nuclear lamina composition during early development of *Xenopus laevis*. *Cell*. 1985, 41 : 191-200.

- Stock J.K, Giadrossi S, Casanova M, Brookes E, Vidal M, Koseki H, Brockdorff N, Fisher A.G et Pombo A. Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells. *Nat Cell Biol.* 2007, 9:1428-1435.
- Stournaras C. Chromatin remodelling and actin organisation. *FEBS Letters.* 2008, 582, (14):2041-2050
- Strahl B.D et Allis C.D. The language of covalent histone modifications. *Nature.* 2000, 403:41-45.
- Strohner R, Nemeth A, Jansa P, Hofmann-Rohrer U, Santoro R, Grummt G et Grummt I. NoRc-a novel member of mammalian ISWI-containing chromatin remodeling machines. *EMBO J.* 2001, 20:4892-4900
- Strouboulis, J., and Wolffe, A. P. Functional compartmentalization of the nucleus. *J. Cell. Biochem. Suppl.* 1996, 24-25: 17-27.
- Sullivan, T., Escalante-Alcalde, D., Bhatt, H., Anver, M., Bhat, N., Nagashima, K., Stewart, C.L. and Burke, B. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. *J Cell Biol.* 1999, 147 : 913-920.
- Sullivan, T., Escalante-Alcalde, D., Bhatt, H., Anver, M., Bhat, N., Nagashima, K., Stewart, C.L. and Burke, B. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. *J Cell Biol.* 1999, 147 : 913-920.
- Sulston, J. E., & Horvitz, H. R. (1977). Post-embryonic cell lineages of the nematode, *Caenorhabditis elegans*. *Developmental Biology*, 56(1), 110-156.
- Suntharalingam, M. and Wenthe, S.R. Peering through the pore: nuclear pore complex structure, assembly, and function. *Dev Cell.* 2003, 4 : 775-789.
- Sweatt, J. D. The emerging field of neuroepigenetics. *Neuron.* 2013, 80(3): 624-632.
- Szulwach K.E, Li X, Li Y, Song C.H, Han J.W, Kim S, Namburi S, Hermetz K, Kim J.J, Rudd M.K, Yoon Y.S, Ren B, He C et Jin P. Integrating 5-hydroxymethylcytosine into the epigenomic landscape of Human embryonic stem cells. *Plos Genet.* 2011; 7:e1002154.
- Tagami H, Ray-Gallet D, Almouzni G, Nakatani Y. Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependant or independant of DNA synthesis. *Cell.* 2004,116:51-61.
- Tahiliani M, Koh K.P, Shen Y, Pastor W.A, Bandukwala H, Brudno Y, Agarwal S, Iyer L.M, Liu D.R, Aravind L et Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science.* 2009, 324:930-935.
- Tan MHE, Li J, Xu HE, Melcher K& Yong EL. Androgen receptor: structure, role in prostate cancer and drug discovery. *Acta Pharmacologica Sinica.* 2015; 36:3–23
- Taniura, H., Glass, C. and Gerace, L. A chromatin binding site in the tail domain of nuclear lamins that interacts with core histones. *J Cell Biol.* 1995, 131 : 33-44.
- Tapscott, S. J., Davis, R. L., Thayer, M. J., Cheng, P. F., Weintraub, H., & Lassar, A. B. MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. *Science.* 1988, 242(4877): 405-411.
- Taylor, M.R., Slavov, D., Gajewski, A., Vlcek, S., Ku, L., Fain, P.R., Carniel, E., Di Lenarda, A., Sinagra, G., Boucek, M.M., Cavanaugh, J., Graw, S.L., Ruegg, P., Feiger, J., Zhu, X., Ferguson, D.A., Bristow, M.R., Gotzmann, J., Foisner, R. and Mestroni, L. Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. *Hum Mutat.* 2005.
- The *C. elegans* Sequencing Consortium. (1998). Genome sequence of the nematode *C. elegans*: a platform for investigating biology. *Science*, 282(5396), 2012-2018.

- Tolhuis B, Palstra R.J, Splinter E, Grosveld F et de Laat W. Looping and interaction between hypersensitive sites in the active β -globin locus. *Mol Cell*. 2002, 10:1453-1465
- Tsukiyama T et Wu C. Purification and properties of an ATP-dependent nucleosome remodeling factor. *Cell*. 1995, 83:1011-1020.
- Tsukiyama T, Palmer J, Landel C.C, Shiloach J et Wu C. Characterization of the imitation switch subfamily of ATP-dependant chromatin-remodeling factors in *saccharomyces cerevisiae*. *Genes Dev*. 1999, 13:686-697.
- Újvári A, Pal M et Luse D.S. RNA polymerase II transcription complexes may become arrested if the nascent RNA is shortened to less than 50 nucleotides. *J Biol Chem*. 2002, 277:32527- 32537
- Vaisanen S, Dunlop T.W, Sinkkonen L, Frank C and Carlberg C. Spatio-temporal activation of chromatin in the human CYP24 gene promoter in the presence of 1 α ,25-Dihydroxyvitamin D3. *J Mol Biol* . 2005, 350:65-77.
- Vakoc C.R, Letting D.L, Gheldof N, Sawado T, Bender M.A, Groudine M, Weiss M.J, Dekker J et Blobel G.A. Proximity among distant regulatory elements at the β -globin locus requires GATA-1 and FOG-1. *Mol Cell*. 2005,17:453-462.
- Varga-Weisz P.D, Wilm M, Bonte E, Dumas K, Mann M et Becker P.B. Chromatin remodeling factor CHRAC contains the ATPases ISWI and topoisomerase II. *Nature*. 1997, 388:598-602.
- Vaughan, A., Alvarez-Reyes, M., Bridger, J.M., Broers, J.L., Ramaekers, F.C., Wehnert, M., Morris, G.E., Whitfield, W.G.F. and Hutchison, C.J. Both emerin and lamin C depend on lamin A for localization at the nuclear envelope. *J Cell Sci*. 2001, 114 : 2577- 2590.
- Vaughan, A., Alvarez-Reyes, M., Bridger, J.M., Broers, J.L., Ramaekers, F.C., Wehnert, M., Morris, G.E., Whitfield, W.G.F. and Hutchison, C.J. Both emerin and lamin C depend on lamin A for localization at the nuclear envelope. *J Cell Sci*. 2001, 114: 2577- 2590.
- Vaughan, A., Alvarez-Reyes, M., Bridger, J.M., Broers, J.L., Ramaekers, F.C., Wehnert, M., Morris, G.E., Whitfield, W.G.F. and Hutchison, C.J. Both emerin and lamin C depend on lamin A for localization at the nuclear envelope. *J Cell Sci*. 2001, 114 : 2577- 2590.
- Vigouroux, C., Auclair, M., Dubosclard, E., Pouchelet, M., Capeau, J., Courvalin, J.C. and Buendia, B. Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q/W mutations in the lamin A/C gene. *J Cell Sci*. 2001, 114 : 4459-4468.
- Visser A.E, Eils R, Jauch A, Little G, Bakker P.J, Cremer T et Aten J.A. Spatial distribution of early and late replicating chromatin in interphase chromosome territories. *Exp Cell Res*. 1998, 243:398- 407.
- Von Mikecz, A., Zhang, S., Montminy, M., Tan, E. M., and Hemmerich, P. CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus. *J. Cell Biol*. 2000, 150(2): 265-273.
- Ward, G.E. and Kirschner, M.W. Identification of cell cycle-regulated phosphorylation sites on nuclear lamin C. *Cell*. 1990, 61: 561-577.
- White, J. G., Southgate, E., Thomson, J. N., & Brenner, S. (1986). The structure of the nervous system of the nematode *Caenorhabditis elegans*. *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences*, 314(1165), 1-340.